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ABSTRACT 
Every fifth pregnant woman is diagnosed with gestational diabetes in Finland. It 
predisposes both the mother and the child to several adverse short- and long-term 
consequences. The presence of obesity is one of the strongest risk factors for 
gestational diabetes. Nutritional factors mainly account for the obesity, and the 
ability to influence these factors could help to prevent gestational diabetes. 
Previous studies suggest that fish oil and probiotic supplements could improve 
insulin sensitivity of the body by decreasing low-grade inflammation and thereby 
prevent gestational diabetes. The aim of this study was to determine whether these 
food supplements could improve glucose levels and reduce the risk of gestational 
diabetes in overweight and obese women. Further, the associations of diet, physical 
activity, and gestational diabetes with maternal body composition were evaluated. 
In the trial, 439 overweight and obese pregnant women were randomized to 
consume probiotics and/or fish oil daily from 15 gestational weeks onwards. Weight, 
body composition, glucose and insulin concentrations were determined in early and 
in late pregnancy. Gestational diabetes was diagnosed with an oral glucose tolerance 
test. Information on diet and physical activity were collected. 
As compared to placebo, intervention with fish oil and probiotics did not reduce 
the risk for gestational diabetes or affect weight or body composition. Three out of 
four women gained weight in excess of recommendations, which was related to 
increased fat mass accrual as compared to women with an ideal weight gain. Protein 
intake and the good quality of diet were positively correlated with fat free mass. 
Body composition in early pregnancy did not differ between healthy women and 
women developing gestational diabetes. Women with gestational diabetes gained 
weight and fat mass less than healthy women. 
In conclusion, according to this study, supplementation with fish oil and/or 
probiotics does not prevent gestational diabetes or affect body fat mass in overweight 
and obese pregnant women. Body adiposity is reduced in women with gestational 
diabetes as compared with healthy overweight or obese women; adiposity increased 
in women with an excess weight gain in comparison with women with an ideal 
gestational weight gain. 
KEYWORDS: adiposity, body composition, diet, fat mass, fish oil, gestational 
diabetes, obese, overweight, pregnancy, probiotics, supplement  
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TIIVISTELMÄ 
Raskausdiabetes on raskaudenaikainen häiriö, joka todetaan Suomessa noin joka 
viidennellä raskaana olevalla naisella. Se lisää sekä äidin että lapsen sairastuvuutta. 
Lihavuus on raskausdiabeteksen tärkein riskitekijä, sillä se heikentää insuliinin 
vaikutusta kudoksissa. Aiempien tutkimusten perusteella kalaöljy- ja probiootti -
ravintolisät saattavat parantaa kehon insuliiniherkkyyttä matala-asteista tulehdusta 
vähentämällä ja siten pienentää raskausdiabeteksen riskiä. Tämän väitöskirja-
tutkimuksen tavoitteena oli selvittää, voidaanko näiden ravintolisien avulla ehkäistä 
raskausdiabetesta ja parantaa verensokeriarvoja, sekä kartoittaa, mitkä tekijät ovat 
yhteydessä raskaudenaikaiseen kehonkoostumukseen. 
Tutkimuksessa 439 ylipainoista äitiä satunnaistettiin neljään ryhmään, jonka 
mukaisesti he käyttivät raskauden ajan päivittäin keskimäärin raskausviikolta 15 
lähtien joko kalaöljyä, probiootteja, molempia tai lumevalmistetta. Äideiltä tutkittiin 
alku- ja loppuraskaudessa paino, kehonkoostumus, verensokeri- ja insuliinipitoi-
suudet ja kerättiin tiedot ravinnonsaannista. Raskausdiabeteksen ilmaantuvuus 
selvitettiin sokerirasituskokeella.  
Äitien raskaudenaikainen kalaöljy- ja/tai probioottilisä ei vähentänyt raskaus-
diabeteksen puhkeamisen todennäköisyyttä tai vaikuttanut äitien kehonkoostu-
mukseen lumevalmisteeseen verrattuna. Kolmella neljästä äidistä paino nousi 
raskausaikana suositukseen nähden liikaa, mikä oli yhteydessä rasvamassan 
lisääntymiseen. Proteiinin saanti ja hyvälaatuinen ruokavalio olivat positiivisesti 
yhteydessä kehon rasvattoman massan määrään. Alkuraskauden kehonkoostumus ei 
ennustanut raskausdiabeteksen puhkeamista ylipainoisilla ja lihavilla äideillä. 
Raskausdiabeetikkoäitien paino ja rasvamassa nousivat raskausaikana vähemmän 
kuin muiden äitien.  
Kalaöljy- ja/tai probioottilisästä ei näyttäisi olevan hyötyä ylipainoisten ja 
lihavien äitien verensokeritasojen, painon tai kehonkoostumuksen hallinnassa. 
Raskausaikana kehonkoostumukseen yhteydessä olevia tekijöitä tämän tutkimuksen 
perusteella ovat tietyt ravintotekijät, raskausdiabetes sekä painonnousu. 
AVAINSANAT: kalaöljy, kehonkoostumus, lihavuus, probiootti, raskaus, raskaus-
diabetes, rasvamassa, ravintolisä, ylipaino  
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DHA docosahexaenoic acid 
DXA Dual-energy X-ray absorptiometry 
EPA eicosapentaenoic acid 
FFM fat free mass 
FM  fat mass 
GDM gestational diabetes mellitus 
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HOMA-IR homeostatic model assessment 
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1 Introduction 
Gestational diabetes (GDM) is an increasingly common condition; around 14% of 
pregnancies are affected worldwide (Guariguata et al. 2014). In Finland in 2018, the 
incidence was 21% according to the statistics of the Finnish Institute of Health and 
Welfare. GDM predisposes both the mother and the child to several short-term and 
long-term complications. The mother is at increased risk of gestational hypertensive 
disorders and requiring a cesarean section, and in later life, the risk of type 2 diabetes 
is 7-fold higher than in women who have a normoglycemic pregnancy (Bellamy et 
al. 2009). The child is predisposed to macrosomia, hypoglycemia, and respiratory 
distress syndrome, and to the programming of obesity and diabetes i.e. fetal 
metabolic adaptation to the in-utero environment causing long-lasting consequences 
(Damm et al. 2016, Nicholas et al. 2016, Reece 2010). 
In the light of this information and considering the 34 % higher costs of care 
related to GDM (Gillespie et al. 2013), prevention of GDM is of major importance. 
Interventions aimed at lowering the risk of GDM have typically focused on lifestyle 
changes. However, these interventions have yielded inconclusive results (Shepherd 
et al. 2017), emphasizing the need for new preventive approaches. 
Insulin resistance plays a critical part in the pathogenesis of GDM (Catalano, P. 
M. 2010). Often the abnormally high insulin resistance is attributable to obesity 
(Buchanan and Xiang 2005). Pregnancy, obesity and GDM are all associated with 
an increase in inflammatory markers that contribute to insulin resistance, and thus a 
heightened inflammatory response has been proposed to play an important role in 
the development of GDM (Abell et al. 2015).  Both probiotics and the n-3 long chain 
polyunsaturated fatty acids (n-3 LC-PUFAs) present in fish oil have been 
demonstrated to possess anti-inflammatory properties and a capability to reduce 
insulin resistance (Calder 2017, Gomes et al. 2014, Lalia and Lanza 2016). 
Furthermore, there is previous experimental evidence indicating that a combination 
of these two active components might exert synergistic immunoregulatory effects 
(Kastel et al. 2007).  
The increasing GDM prevalence is related to the growing prevalence of 
overweight and obesity, which enhance the risk of developing GDM by 2-10-fold 
(Chu et al. 2007, Gaillard et al. 2013). Approximately every third woman of 
Outi Pellonperä 
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reproductive age in Europe and more than every second woman in the United States 
is overweight or obese (Ogden et al. 2014, Ovesen et al. 2011). Body mass index 
(BMI) is often used as a marker of adiposity. However, body composition reflects 
nutritional status and provides more precise information about the adiposity of the 
body than BMI (Lindsay, C. A. et al. 1997, Prentice and Jebb 2001). Further, it has 
been found that body composition and fat distribution correlate better with insulin 
sensitivity than BMI also in pregnant women (Gur et al. 2014, Sommer et al. 2014). 
However, little is known about the actual body composition of women diagnosed 
with GDM, or how body composition changes during pregnancy as compared to 
women without GDM.  
Furthermore, the means to regulate body adiposity during pregnancy have been 
poorly studied, even if the degree of adiposity rather than mere weight gain is likely 
to be better associated with the onset of pregnancy complications. The consumption 
of n-3 LC-PUFA has been proposed to modestly reduce weight and body fat 
percentage (BF%) in non-pregnant individuals (Bender et al. 2014). Additionally, 
the previous literature suggests that also probiotics may help weight loss and fat mass 
loss in overweight adults, especially if provided as certain strains of Lactobacillus 
and Bifidobacterium (Borgeraas et al. 2018, Crovesy et al. 2017). The effects of these 
supplements on body composition during pregnancy are unknown. 
The purpose of the studies in this thesis was to examine whether an intervention 
with n-3 LC-PUFA and/or probiotics could exert favorable effects on maternal 
glucose control and body composition. Furthermore, the relationship of lifestyle 
factors and the presence of GDM on maternal body composition was evaluated. 
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2 Review of the Literature 
2.1 Gestational diabetes mellitus (GDM) 
2.1.1 Glucose metabolism in uncomplicated pregnancy 
During a normal pregnancy, hormone-regulated metabolic changes occur to ensure 
the adequate transfer of nutrients to the fetus. Pregnancy induces a progressive 
insulin resistance that begins in mid-pregnancy and increases gradually as pregnancy 
progresses (Catalano, P. M. et al. 1991, Catalano, P. M. et al. 1999). The placenta 
produces tumor necrosis factor α (TNF-α), placental lactogen, and growth hormone, 
which in combination with enhanced cortisol and progesterone levels are thought to 
result in increased insulin resistance (Catalano, P. M. 2010, Di Cianni et al. 2003). 
In order to maintain normoglycemia in the mother, hypertrophy and hyperplasia of 
pancreatic beta cells occur and the production of insulin increases (Baeyens et al. 
2016). The enhanced maternal basal endogenous hepatic glucose production further 
augments glucose transport to the fetus through the placenta (Catalano, P. M. et al. 
1992). By the end of the third trimester, insulin sensitivity is halved, hepatic glucose 
production increased by 30%, and insulin secretion by 200% (Catalano, P. M. et al. 
1999).  
2.1.2 Pathogenesis of GDM 
Gestational diabetes is defined as hyperglycemia during pregnancy that is not overt 
diabetes (American Diabetes Association 2018). Women unable to adapt to the 
normal pregnancy-induced physiological changes, develop GDM. The pathogenesis 
of GDM consists of two main factors: high insulin resistance and a decreased ability 
of pancreatic beta cells to produce enough insulin (Buchanan 2001, Catalano, P. M. 
2010) (Figure 1). In women with GDM, β-cell dysfunction and increased insulin 
resistance are present already before pregnancy, although insulin secretion is still 
sufficient to maintain normoglycemia (Buchanan et al. 2007, Catalano, P. M. et al. 
1993). During pregnancy, hyperglycemia emerges when pancreatic β-cells become 
too exhausted to produce enough insulin to overcome the increasing insulin 
resistance caused by placental hormones and the possible excessive gestational 
  
Figure 1. Factors contributing to maternal glucose metabolism and fetal complications. GDM=gestational diabetes, GWG= gestational weight gain, 
PCOS=polycystic ovary syndrome, TNF-α= tumor necrosis factor alpha, RDS=respiratory distress syndrome. Modified from reviews by Agha-
Jaffar et al. 2016, Hod et al. 2015, Plows et al. 2018. 
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weight gain (GWG). Some women with GDM suffer predominantly from an insulin 
secretion disorder, while in others, the primary underlying cause is insulin resistance 
(Powe et al. 2016). This makes GDM a heterogenous condition e.g. it might reflect 
the different genetic background of the women. Women with a predominantly 
insulin secretion disorder have more commonly BMI and the risk of pregnancy 
complications resembling normoglycemic women (Powe et al. 2016). However, 
most women have primarily obesity related enhanced insulin resistance underlying 
GDM, and they are more prone to complications related to the obesity (Powe et al. 
2016).  
2.1.2.1 Insulin resistance related to obesity 
Obesity related excessive insulin resistance is suggested to be partly mediated 
via inflammatory processes in the adipose tissue. The immune cells within adipose 
tissue are regulated by different stimuli such as diet, body weight, and the ingestion 
of excess calories that can cause metabolic distress. As a result, immune cells can 
switch from anti-inflammatory subtypes towards more the pro-inflammatory 
subtypes (Grant and Dixit 2015). Although uncomplicated pregnancy is 
characterized as a state of mild maternal systemic inflammation, excessive adipose 
tissue and placental inflammation are associated with several gestational disorders 
including GDM (Kuzmicki et al. 2009). The inflammation is demonstrated by higher 
circulating levels of pro-inflammatory cytokines in women with GDM as compared 
to normoglycemic women, e.g. increased levels of TNF-α, interleukin-6, and 
interleukin-1β have been detected (Ategbo et al. 2006, Fasshauer et al. 2014).  
Plasma TNF-α, especially, is clearly related to insulin resistance (Kirwan et al. 
2002). Likewise, the placental gene expressions of TNF-α, interleukin-1β and their 
receptors have been shown to be enhanced in GDM (Kirwan et al. 2002, Radaelli et 
al. 2003). These cytokines have been found to both reduce insulin release from β-
cells, and impair insulin signaling, thus inducing insulin resistance (Barbour et al. 
2007, Kim et al. 2009). 
Adiponectin, a hormone that is mainly secreted by adipocytes, has also been 
proposed to play a role in the pathogenesis of GDM. Obesity and GDM are both 
associated with reduced adiponectin levels (Williams et al. 2004), but there is a 
greater inverse correlation of adiponectin with insulin resistance than with adiposity 
(Retnakaran et al. 2004). This could indicate that adiponectin has a part in the 
pathogenesis of GDM, independent of obesity. Adiponectin has been found to 
increase insulin signaling and fatty acid oxidation, and hinder gluconeogenesis 
(Yamauchi et al. 2002). Moreover, it promotes insulin secretion by augmenting 
insulin gene expression and exocytosis of insulin granules from β-cells (Kishida et 
al. 2012). 
Outi Pellonperä 
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Systemic insulin resistance can also be promoted by inflammation that is 
mediated by an obesogenic diet and dysbiosis of microbiota, which may enhance gut 
permeability and enable the passage of inflammatory mediators from the gut into the 
circulation (Backhed et al. 2005, Jayashree et al. 2014). Gut permeability is 
controlled by tight junction proteins, such as zonulin, and enhanced zonulin 
concentrations have been detected in early pregnancy in women that later develop 
GDM (Mokkala, Tertti et al. 2017).  
Finally, excessive accretion of fat mass (FM) in obesity results in inadequate 
storage capacity of adipose tissue for lipids and, hence lipotoxic damage of insulin 
signaling in peripheral tissues and low-grade inflammation (Herrero et al. 2010). 
This lipolysis, with the increased release of free fatty acids and hepatic glucose 
production, has also been suggested to induce insulin resistance during pregnancy 
(Barbour et al. 2007, Buchanan et al. 1990, Catalano, P. M. et al. 1991). All in all, 
placental hormones, chronic inflammation, and excess lipolysis are essential in the 
pathogenesis of insulin resistance in GDM. After the delivery, pregnancy-induced 
insulin resistance resolves within a few days and the woman returns to her 
prepregnancy glycemic stage (Ryan et al. 1985).  
2.1.3 Risk factors 
Several factors predispose a woman to GDM (Figure 1). They are generally related 
to either pre-existing insulin resistance, decreased insulin secretory capacity, or 
enhanced insulin resistance caused by pregnancy (Ben-Haroush et al. 2004). Genetic 
characteristics play an important role in the background of these features. 
Well established risk factors for GDM include being overweight or obese, as a 
linear increase in the risk of GDM with an increase in maternal BMI has been 
detected. The GDM risk has been shown to rise by 4% per unit of increase in BMI, 
which translates to odds ratios 2.0 for overweight women and 4.0 for obese women 
as compared to normal weight women (Najafi et al. 2019). Gestational weight gain 
is also an important risk factor for GDM, as over 40% of women who gain weight in 
excess of the recommendations of Institute of Medicine (IOM) during the first 
trimester of pregnancy, develop GDM (Carreno et al. 2012, Hedderson et al. 2010). 
Furthermore, parity is a risk factor independent of age (Ben-Haroush et al. 2004). 
Other predisposing factors include ethnicity (Caughey et al. 2010), genetic 
polymorphisms (Huopio et al. 2013), advanced maternal age (Lao et al. 2006), prior 
macrosomic newborn (Pintaudi et al. 2013), systemic corticosteroid medication 
(Yildirim et al. 2006), family history of type 2 diabetes (Levy et al. 2010, 
Mustaniemi et al. 2018, Ogonowski et al. 2007), personal history of GDM 
(Mustaniemi et al. 2018), and other conditions of insulin resistance, such as 
polycystic ovary syndrome (Ben-Haroush et al. 2004).  
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Although less thoroughly studied, there are some indications that a distinct 
metabolomic profile (Mokkala, Vahlberg et al. 2019), and high triglyceride levels 
(Li et al. 2015) in early pregnancy are a characteristic feature in women who develop 
GDM. Additionally, consumption of diets that have abundantly saturated fats, 
refined sugars, and red and processed meats have been suggested to be related to an 
enhanced risk of GDM (Bowers et al. 2012, Zhang, C. et al. 2006). It has been 
proposed that saturated fats affect insulin signaling and provoke inflammation (Sivan 
and Boden 2003). 
2.1.4 Implications to the mother and child 
As GDM can cause several consequences for both the mother and the fetus (Table 
1), it is important to understand and effectively prevent or treat GDM. The magnitude 
of the risk for each outcome varies according to the diagnostic criteria applied and 
the study population. 
GDM affects the health of mother acutely and over the long term. The risk of 
gestational hypertensive disorders and pre-eclampsia is higher than in 
normoglycemic women (Yogev et al. 2004). In Finland, about 20% of GDM women 
develop either gestational hypertension or pre-eclampsia (Suhonen and Teramo 
1993). There is also an increased risk of macrosomic infant, preterm birth and need 
for cesarean section (HAPO Study Cooperative Research Group et al. 2008). 
Additionally, maternal glycemic status has been found to display positive linear 
associations with the induction of labor, large for gestational age infant, and with 
shoulder dystocia, with no obvious sign of a threshold effect. It seems that the fasting 
concentration is better correlated with these outcomes than the post-load 
concentration (Farrar et al. 2016). 
In later life, these women have a higher risk of type 2 diabetes, metabolic 
syndrome and cardiovascular disease. According to a recent large observational 
study examining over four thousand Danish and North American women, the 
progression from GDM to type 2 diabetes was 23% in US women over 23 years and 
27% in Danish women within 9 years (Zhang, C. et al. 2019). Furthermore, it was 
shown that the risks of hypertension and cardiovascular diseases, as well as early 
stages of renal damage were clearly higher in women with GDM. Similarly, in 
Finland, women with two or more abnormal values in the oral glucose tolerance test 
(OGTT) during pregnancy had a 25% risk of later type 2 diabetes and a 62.5% risk 
of metabolic syndrome after 10 years of follow-up, as compared to 0.8% and 24.2% 
of normoglycemic women, respectively (Hakkarainen 2019). 
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Table 1.  Short- and long-term risks for the mother and the child in pregnancies complicated by 
gestational diabetes.   
Short-term risks OR (95% CI) Long-term risks OR (95%CI) 
Pre-eclampsia or PIH1 a  3.8  
(1.5-9.9) 
Mother  
Macrosomiab 2.7  
(1.9-3.7) 
Type 2 diabetesc 5.4  
(3.7-7.9) 
Large for gestational ageb 3.3  
(2.5-4.6) 
Hypertensiond 1.26  
(1.1-1.4)2 
Cesarean deliveryb 1.9  
(1.5-2.4) 
Metabolic syndromee 3.4  
(2.5-4.8) 
Shoulder dystociab 4.1  
(1.6-10.2) 
  
Neonatal hypoglycemiab 10.4  
(6.5-16.6) 
Child  
Neonatal respiratory 
complicationb 
4.4  
(2.9-6.8) 
Type 2 
diabetes/prediabetesf 
7.8  
(2.6-23.4) 
Neonatal 
hyperbilirubinemiab 
3.9  
(2.6-5.7) 
Obesityc 1.6  
(1.2-2.0) 
1 Pregnancy induced hypertension.2Hazard ratio. Adapted from aSuhonen et al. 1993, bLanger et al. 
2005, cLowe et al. 2018, dTobias et al 2011, eLauenborg et al. 2005, fClausen et al. 2008.  
GDM also affects the short- and long-term health of the infant (Table 1). The 
enhanced placental delivery of glucose, amino acids, and fatty acids stimulate the 
fetus’s endogenous production of insulin and insulin-like growth factor 1 (Figure 1). 
This can result in fetal macrosomia at birth (Schwartz et al. 1994), which is a risk 
factor for shoulder dystocia. Due to the fetal hyperinsulinemia, these infants are at 
an increased risk of hypoglycemia. There is also evidence that GDM increases the 
risk of respiratory distress syndrome, hyperbilirubinemia and stillbirth (Langer et al. 
2005, Reece 2010).  
In the long term, the offspring of women with GDM display higher weights, 
BMI, systolic blood pressure, fasting blood glucose, insulin, insulin resistance 
(assessed by homeostatic model assessment, HOMA-IR) and triglycerides, as 
revealed by the results of the Danish National Birth Cohort that examined offspring 
at a mean twelve years of age (Grunnet et al. 2017). Even after adjustment for 
maternal prepregnancy BMI, the offspring of mothers with GDM had significantly 
higher BMI, fasting glucose, and HOMA-IR levels. In another large study, it was 
found that maternal GDM was independently associated with the offspring’s risk of 
abnormal glucose tolerance, obesity, and higher blood pressure at 7 years of age 
(Tam, W. H. et al. 2017). Females are hence more prone to develop GDM in their 
own pregnancies, contributing to a vicious intergenerational cycle of GDM (Lee et 
al. 2000). These long-term risks could be partially due to the similar genetic factors, 
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dietary patterns, and physical activity levels in their families (Najafi et al. 2019). 
However, the findings may also be explained by the programming effects of 
hyperglycemia in pregnancy (Nicholas et al. 2016). 
2.1.5 Diagnosis 
GDM can be diagnosed with a one-phase 2-hour 75 g OGTT or a two-phase 3-h 100-
g OGTT. Since the first introduction of diagnostic criteria for GDM in 1960s by 
O’Sullivan and Mahan (O'Sullivan and Mahan 1964), the type of OGTT and criteria 
for diagnosing GDM have varied over the decades and around the world. 
Furthermore, some countries prefer risk-based screening, while others endorse 
universal screening. These variations have complicated the interpretation of research 
results. Therefore, during the past decade, the scientific community has sought to 
uniform the screening of GDM, although with limited progress.  Recently, the most 
widely accepted diagnostic criteria internationally have been the criteria 
recommended by the International Association of Diabetes and Pregnancy Study 
Group (IADPSG) (International Association of Diabetes and Pregnancy Study 
Groups Consensus Panel et al. 2010), which are also endorsed by the American 
Diabetes Association and the World Health Organization. These criteria were 
developed based on the findings of the Hyperglycemia and Adverse Pregnancy 
Outcomes (HAPO) -study demonstrating a direct association between glucose 
concentrations in the 75 g OGTT and adverse pregnancy and neonatal outcomes 
(HAPO Study Cooperative Research Group et al. 2008). According to the IADPSG 
recommendation, all women not known to have diabetes should undergo a one-phase 
75-g OGTT at 24–28 gestational weeks and be diagnosed with GDM if one or more 
values meet or exceed the cut-off values of 5.1mmol/l (0h) -10.0 mmol/l (1h) -8.5 
mmol/l (2h). One important finding of the HAPO Study and another large study by 
Farrar et al. 2016, was that there was a continuous risk of maternal and fetal 
complications with increasing maternal glycaemia, which makes all diagnostic 
thresholds somewhat arbitrary. Nonetheless, the lower cut-off values with IADPSG 
criteria find more women and children at risk of GDM related complications as 
compared to more traditional higher cut-off values (International Association of 
Diabetes and Pregnancy Study Groups Consensus Panel et al. 2010, Lowe et al. 
2018), and these women and children could benefit from the treatment of GDM. As 
risk-based screening is known to miss a significant proportion of women with GDM, 
universal screening is recommended (Farrar et al. 2017).  
In Finland, GDM is diagnosed with the criteria issued by Finnish Current Care 
Guidelines (Working group established by the Finnish Medical Society Duodecim 
2008). All women, except women at very low risk, i.e. women 1) <25 years of age 
with normal BMI, and no family history of diabetes or 2)  <40 years of age, with 
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normal BMI and a previous normoglycemic pregnancy without fetal macrosomia, 
are screened for GDM at 24-28 weeks of gestation with one-phase 75 g OGTT. 
Thresholds in the OGTT are ≥5.3, ≥10.0, and ≥8.6 mmol/l for 0, 1, and 2 hours, 
respectively, and one value meeting or exceeding the cut-off is enough for a 
diagnosis. With these criteria, approximately every fifth woman is diagnosed with 
GDM (Perinatal statistics, Finnish Institute of Health and Welfare 2018, www.thl.fi). 
Moreover, women at a high risk of GDM are recommended to be screened with the 
same threshold values already between 12 and 16 gestational weeks. This early 
OGTT is recommended for women with a BMI ≥ 35 kg/m2, previous GDM, early 
glucosuria during pregnancy, polycystic ovary syndrome, oral glucocorticoid 
medication, or a family history of diabetes. Women with an early diagnosis of GDM 
represent a high-risk subgroup, with an increased incidence of obstetric 
complications, recurrent GDM in subsequent pregnancies, and the future 
development of Type 2 diabetes (Ben-Haroush et al. 2004). The identification and 
treatment of GDM in these women already in early pregnancy may reduce the risks 
of obstetric complications.  
2.1.6 Treatment 
The treatment of GDM, including medication when needed, has been shown to 
reduce pre-eclampsia, infant macrosomia, shoulder dystocia and cesarean delivery 
(Hartling et al. 2013, Landon et al. 2009). In Finland, all women with GDM are 
offered lifestyle counselling and equipment for self-monitoring of glucose 
concentrations at local maternal welfare clinics. Lifestyle counselling consists of 
dietary advice and recommendations for physical activity, as instructed in the 
Finnish Current Care Guidelines (Working group established by the Finnish Medical 
Society Duodecim 2008). If the target values (<5.5 mmol/l for fasting glucose and 
<7.8mmol/l for 1h postprandial glucose) are repeatedly exceeded despite 
conservative treatment, medication is offered. Depending on gestational weeks, 
maternal characteristics, the severity of GDM and whether fasting or postprandial 
glucose concentrations are the main issue, either insulin or metformin medication is 
initiated. 
2.2 Prevention of gestational diabetes mellitus 
2.2.1 Lifestyle interventions 
Physical activity during pregnancy has been found to be safe and might even reduce 
the risk of preterm birth (Beetham et al. 2019, Magro-Malosso et al. 2017). 
Interventions to prevent GDM by enhancing physical activity have yielded positive 
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results, as several recent reviews/meta-analyses conclude that exercise can reduce 
the incidence of GDM by 20–40% (Davenport et al. 2018, Dipietro et al. 2019, 
Magro-Malosso et al. 2017, Russo et al. 2015). Most of the interventions in these 
RCT studies seem to have involved mainly aerobic activity of moderate intensity, 
such as walking, swimming, and aerobic exercise, taking place at least three times a 
week for a duration of 30 - 60 minutes per session (Dipietro et al. 2019). 
Diet interventions to reduce the incidence of GDM have generated conflicting 
results. According to Cochrane systematic review (Tieu et al. 2017), low quality 
evidence suggests that the GDM risk of women could be reduced by dietary advice 
versus standard care. Regarding the diets that have been investigated, a DASH-
style diet (The Dietary Approach to Stop Hypertension) compared to other diets, 
was found to improve fasting glucose (Ha et al. 2017). Similarly, the risk of GDM 
was reduced by a high adherence to a Mediterranean diet as compared with women 
with low adherence (Assaf-Balut et al. 2018). Meanwhile, several studies have not 
found any consistent correlation between diet quality and glycaemia (Simmons 
2019). All in all, it is evident that better nutritional approaches are needed to 
prevent GDM.  
Multiple intervention trials combining diet and exercise have been conducted in 
an attempt to prevent GDM, such as the LIMIT, UPBEAT and DALI trials, with no 
reduction in the risk of GDM or insulin sensitivity (Dodd et al. 2014, Poston et al. 
2015, Simmons et al. 2017). Recent meta-analyses have found more promising 
results, indicating that there could be a reduced risk of GDM in the diet and exercise 
intervention groups as compared with the standard care groups (Guo et al. 2019, 
Shepherd et al. 2017). Furthermore, the Finnish RADIEL trial showed that women 
with a high risk for GDM (history of GDM or BMI ≥30kg/m2) could benefit from 
combined diet and physical activity counselling in terms of reducing GWG and the 
incidence of GDM (Koivusalo et al. 2017). The reason for the discrepant results 
between studies has been proposed to be the substantial heterogeneity between the 
interventions, the differing characteristics of the trial participants, the settings of 
trials, and differences in the screening of GDM and diagnostic criteria. In addition, 
the adherence to the intervention (which has been reported to be low in many 
studies), and the fact that pregestational glucose intolerance is not screened before 
randomization, may be confounding factors. The genetic background can also affect 
the responsiveness to the intervention, as suggested by the results of the RADIEL 
study (Grotenfelt et al. 2016).  
It has been proposed that the risk of GDM can only be reduced if interventions 
are started in or before the first trimester and the women are willing to adhere to the 
intervention (Egan and Simmons 2019). Furthermore, due to the heterogeneity of 
GDM, it is likely that interventions to prevent GDM will need to be individualized, 
according to the subject’s characteristics. Other key aspects in the improvement of 
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lifestyle intervention outcomes could include targeting other than BMI-based high-
risk populations, determining the correct intensity and frequency of exercise, and 
GWG management (Guo et al. 2019). 
All in all, it seems that lifestyle approaches to reduce the risk of GDM are not 
effective for many women at risk and new means to prevent GDM are clearly 
needed. 
2.2.2 N-3 long chain polyunsaturated fatty acids 
N-3 (or omega-3) fatty acids belong to a family of long chain poly-unsaturated fatty 
acids (LC-PUFA), which are vital for the functioning of the body (Simopoulos 2002, 
Surette 2008). As opposed to saturated fatty acids that are more solid and have no 
double bonds, n-3 fatty acids are soft and contain three or more double bonds. The 
term ‘n’ or omega (ω), refers to the position of the first double bond, i.e. n-3 LC-
PUFA possesses the first double bond between the third and fourth carbon atoms 
(Anderson, B. M. and Ma 2009). The major n-3 LC-PUFAs are α-linolenic acid 
(ALA 18:3n-3), eicosapentaenoic acid (EPA 20:5n-3) and docosahexaenoic acid 
(DHA, 22:6n-3) (Anderson, B. M. and Ma 2009). PUFAs are present in all cell 
membranes and contribute to membrane fluidity and the function of membrane-
bound enzymes and receptors, and thus influence many metabolic processes (Surette 
2008, Wall et al. 2010). Because n-3 LC-PUFA ALA cannot be synthesized by the 
body, it is termed ‘essential’ and must be obtained from the diet (Sprecher et al. 
1995). Important sources of ALA include different kinds of plant oils. To a small 
degree, ALA can be converted in the body to biologically active derivatives DHA 
and EPA (Burdge et al. 2002, Emken et al. 1994). EPA and DHA can be found in 
some species of fish and seafood (Ellulu et al. 2015, Surette 2008). They can also be 
consumed as nutritional supplements, such as fish oil capsules.  
DHA and EPA are precursors to a range of compounds that are known to reduce 
and help resolve inflammatory responses and oxidative stress, as has been shown in 
animal and in vitro studies (Calder 2006, Chapkin et al. 2009, Ellulu et al. 2015, 
Wall et al. 2010). Several mechanisms have been suggested to underpin the anti-
inflammatory properties of the n-3 LC-PUFAs, although the precise molecular 
mechanisms are not completely understood. First, they can interact with the major 
inflammatory signaling pathways and reduce pro-inflammatory cytokine levels, as 
has been shown in animal and human studies (Calder 2011, Lorente-Cebrian et al. 
2015). Second, inflammation can be reduced by n-3 LC-PUFA supplementation via 
disruption of pro-inflammatory eicosanoid production or augmenting the production 
of anti-inflammatory forms (Calder 2003). Third, it has been suggested that an 
essential part of the anti-inflammatory effect of n-3 LC-PUFAs is their ability to alter 
inflammatory gene expression through influencing transcription factors such as 
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nuclear factor kappa B (NFkB) and peroxisome proliferator-activated receptors 
(PPARs)(Calder 2006, de Castro et al. 2015). Furthermore, one of the important 
causes in increasing the obesity-related inflammatory response has been recognized 
to be the Toll-like receptor 4 signaling pathway, which can be attenuated by DHA 
and EPA (Rogero and Calder 2018). This attenuation in macrophages in muscle has 
been shown to improve markers of inflammation (TNF-α, CRP, interleukin-6) and 
insulin resistance (Liu et al. 2013, Smith et al. 2010). Finally, n-3 LC-PUFA 
supplementation can modify gut microbiota composition and thereby enhance 
intestinal integrity and reduce LPS-mediated metabolic endotoxemia and 
inflammation (Mokkala, Houttu et al. 2019). 
However, despite solid evidence in favor of DHA and EPA being able to reduce 
insulin resistance from animal and mechanistic studies (Flachs et al. 2014, Lamping 
et al. 2013), findings from human clinical trials on glycemic control and insulin 
resistance have been equivocal (Coelho et al. 2017). In a recent meta-analysis, which 
evaluated the effects of fish oil supplementation in human RCTs, fish oil 
supplementation was found to have no effects on insulin sensitivity as compared with 
the placebo (Gao et al. 2018). Nevertheless, in a subgroup analysis, it was observed 
that short-term fish oil supplementation was related to improved insulin sensitivity 
among people with metabolic disorders (Gao et al. 2018). In another meta-analysis 
in type 2 diabetic patients, it was concluded that although n-3 LC-PUFA 
supplementation did not affect the glucose control, the level of triglycerides was 
reduced and a high ratio of EPA/DHA led to an almost statistically significant 
decrease in plasma insulin and HbA1c levels (Chen, C. et al. 2015). Still, caution 
with high doses (≥4g daily) of n-3 LC-PUFA supplementation is warranted, as they 
could even worsen glycemic control (Puhakainen et al. 1995, Woodman et al. 2002). 
Although the causes of the effects of dietary interventions can be complex, and thus 
must be separated from interventions with supplementation, it has been postulated 
that replacing carbohydrates or saturated fatty acids with PUFA in human diet would 
be one way to induce improvements in glycaemia, insulin resistance and insulin 
secretion capacity (Imamura et al. 2016).  
The pregnancy is a period of increased risk for n-3 LC-PUFA deficit as these 
compounds are used by the developing fetus (Gil-Sanchez et al. 2010, Makrides and 
Gibson 2000, Otto et al. 1997). Thus, it is typical that the maternal serum DHA levels 
decrease during the pregnancy (Al et al. 2000). It has been stated that pregnant 
women should increase their DHA intake to 200 mg/day (Koletzko et al. 2007). The 
same is recommended in Finland (Finnish Institute of Health and Welfare, 
https://thl.fi/fi/web/elintavat-ja-ravitsemus/ravitsemus/syodaan-yhdessa-ruokasuo-
situkset-lapsiperheille). However, it has been proposed that only about one in four 
women meets this recommendation (Jia et al. 2015), although it has been 
demonstrated that regular consumption of fish oil results in enhanced concentrations 
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of n-3 LC-PUFA in the maternal circulation and in cord blood (Miles et al. 2011, 
Min et al. 2014). Additionally, placental and fetal tissue concentrations of n-3 LC-
PUFAs have been found to correlate positively with their respective concentrations 
in maternal blood during late pregnancy (Jones et al. 2013). However, fish intake is 
low in many countries, and pregnant women may be unwilling to increase their fish 
intake due to perceptions that the presence of mercury and other pollutants in fish 
may affect their unborn child (Bloomingdale et al. 2010).  
It has been suggested in a few observational studies that there is an association 
with low dietary PUFA intake and gestational hyperglycemia (Bo et al. 2001, Wang, 
Y. et al. 2000). In addition, DHA concentrations in red blood cell membranes have 
been shown to be lower in women with GDM as compared to the concentrations in 
women with normoglycemic pregnancies (Taschereau-Charron et al. 2017). 
Additionally, alterations in the molecular mechanisms regulating placental fatty acid 
transport have been reported in patients with GDM (Magnusson et al. 2004). As is 
the case in a non-pregnant population, the n-3 LC-PUFA have been detected to exert 
both antioxidant and anti-inflammatory properties also in pregnant women (Haghiac 
et al. 2015, Jones et al. 2014, Leghi and Muhlhausler 2016). The increase in placental 
membrane DHA after DHA supplementation was associated with a reduction in 
inflammatory markers, along with an increase in fatty acid transport capacity (Lager 
et al. 2017). Similar results were found in another study, as supplementation of 
overweight/obese pregnant women with DHA and EPA reduced inflammation in 
maternal adipose and the placental tissue (Haghiac et al. 2015).  
Despite these promising mechanistic studies, human trials with n-3 LC-PUFA 
supplementation have not succeeded in preventing GDM, as summarized in Table 2. 
In addition, a meta-analysis of randomized controlled studies, primarily with the 
main outcomes other than GDM, have failed to demonstrate any benefit of 
consuming n-3 LC-PUFA on the incidence of GDM (Chen, B. et al. 2015).  A 
number of studies have also been conducted in women already diagnosed with 
GDM; a recent meta-analysis of 7 randomized controlled trials reported evidence of 
a benefit on glucose metabolism and insulin resistance associated with n-3 LC-PUFA 
consumption (Gao et al. 2018). In contrast, a Cochrane review on Omega-3 fatty acid 
addition during pregnancy did not detect improvements in insulin resistance 
(Middleton et al. 2018).  
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Table 2. Randomized controlled trials on n-3 LC-PUFA with information on gestational diabetes 
(GDM).  
Author Country Year Sample 
size 
Intervention and 
daily dose 
Start/End Main 
outcome 
Result 
Harper et al.  USA 2010 852 DHA 800mg, EPA 
1200 mg + 17-α 
hydroxyprogesterone 
caproate 
16–21+6 gw/ 
delivery or 
36+6 gw 
Preterm 
birth < 37 
gw 
No difference in 
the incidence of 
GDM 
Zhou et al. Australia 2012 2399 DHA 800 mg 
EPA 100 mg 
<21gw (mean 
19.0 gw) / 
delivery 
GDM 
(OGTT ~ 
28 gw) 
No difference in 
the incidence of 
GDM 
Hauner et al. Germany 2012 208 DHA 1020 mg 
EPA 180 mg + 
dietary advice 
<h15 / 4 
months 
postpartum 
Offspring 
body 
composition 
No difference in 
the incidence of 
GDM 
Carlson et al. USA 2013 301 DHA 600 mg <20 gw/ 
delivery 
Duration of 
gestation 
No difference in 
the incidence of 
GDM 
Mozurkewich 
et al. 
USA 2013 118 DHA 274 mg +EPA 
1060 mg OR DHA 
900 mg + EPA 180 mg  
12-20 gw/  
6–8 wk 
postpartum 
Depression No difference in 
the incidence of 
GDM 
Bisgaard et 
al. 
Denmark 2016 695 DHA 890 mg 
EPA 1320 mg 
24 gw/1 wk 
after delivery 
Wheeze, 
asthma 
No difference in 
the incidence of 
GDM 
DHA= docosahexaenoic acid, EPA= eicosapentaenoic acid, gw= gestational weeks, OGTT= oral 
glucose tolerance test, wk= weeks. 
2.2.3 Probiotics 
The gut microbiota has been shown to have an influence on several pathological 
conditions in rodents and humans, such as obesity and insulin resistance (Backhed et al. 
2004, Le Chatelier et al. 2013, Vrieze et al. 2012). In animals, it has been shown that 
germ-free mice are resistant to obesity, and after transplantation of gut microbes, the 
animals are likely to increase their energy intake and develop fat deposition and insulin 
resistance (Backhed et al. 2004, Backhed et al. 2007). Moreover, mice that were 
colonized with gut microbiota from obese animals harvested energy more efficiently and 
accumulated body fat more quickly (Turnbaugh et al. 2006). Clinical studies in humans 
also support the connection between gut microbiota and obesity (Duncan et al. 2008, Ley 
et al. 2006). Therefore, it has been proposed that interventions that modify the gut 
microbiota and its functions could also impact on the metabolic health of the host. 
Probiotics are ‘live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host’, as defined by World Health 
Organization (Joint FAO WHO Working Group 2002). The Lactobacillus, 
Bifidobacterium and Bacteroides are the genera that have often been associated with 
a reduction of FM, adipose tissue inflammation or improved glycemic control 
(Gauffin Cano et al. 2012, Plovier and Cani 2017). However, it is likely that the 
Outi Pellonperä 
26 
benefits induced by probiotics are dependent on the specific species or even which 
strains are used (Torres et al. 2019). 
The potential effects of probiotics are mediated in several mechanisms, which are 
still not completely understood. For example, probiotics can break down ingested 
complex polysaccharides into short-chain fatty acids. There is evidence that these fatty 
acids act at various levels to reduce the inflammatory state which in turn, decreases 
insulin resistance and improves β-cell function (Puddu et al. 2014, Yadav et al. 2013).  
An additional suggested mechanism of probiotics is their ability to enhance the gut 
epithelial barrier integrity (Anderson, R. C. et al. 2010, Dai et al. 2012). Intestinal 
permeability is enhanced by dysbiosis of the microbiota, which leads to adipose tissue 
inflammation through a process where lipopolysaccharide from the cell walls of gram-
negative bacteria, binds to the Toll-like receptor 4, which in turn induces the activation 
of NFkB (Wu et al. 2012). The favorable effects of probiotics can also be induced by 
the competitive exclusion of pathogenic bacteria in the gut (Mazloom et al. 2019). 
Furthermore, an essential mechanism of probiotics is their ability to attenuate chronic 
inflammation by modulation of immune responses of the host. Numerous probiotic 
strains, such as Lactobacillus rhamnosus GG, have been recognized as inhibitors of 
NFkB mediated chronic systemic inflammation (Tien et al. 2006, Zhang, L. et al. 
2005). Other proposed anti-inflammatory effects of probiotics include their abilities to 
1) regulate the maturation of dendritic cells in the gut 2) induce the generation of anti-
inflammatory rather than inflammatory cytokines and 3) induce the differentiation of 
T-helper cells into Th2 cells (Torres et al. 2019). Probiotics might also be able to 
modulate the secretion of adipokines in the adipose tissue, leading to the suppression 
of pro-inflammatory cytokines and/or enhanced production of adiponectin in 
adipocytes (Fabersani et al. 2017, Novotny Nunez et al. 2015). 
According to human clinical trials, probiotics can help in weight loss, reduction 
of BMI or FM, as several recent meta-analyses have described (Borgeraas et al. 
2018, Dror et al. 2017, John et al. 2018, Koutnikova et al. 2019). However, the effect 
sizes were relatively small. The benefits were seen especially among overweight 
subjects and the mean duration of intervention was around 8 weeks. Different strains 
of probiotics were used, and the duration of intervention has varied, and additionally, 
a variety of effects on the gut microbiota was discovered. The benefits were 
primarily detected with mixtures containing bifidobacteria (B. breve and B. longum), 
Streptococcus salivarius subsp. thermophilus and lactobacilli (L. acidophilus, L. 
casei, L. delbrueckii) with most of the trials yielding benefits being conducted in 
Iran. Probiotic consumption may also modestly improve glycemic control in humans 
(Koutnikova et al. 2019, Nikbakht et al. 2018, Ruan et al. 2015). This was detected 
especially in subjects with type 2 diabetes (Koutnikova et al. 2019, Nikbakht et al. 
2018). The probiotic species and the dose used have varied between studies. 
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In an uncomplicated pregnancy, the maternal gut microbiota changes from first 
to third trimester (Gomez-Arango et al. 2016, Koren et al. 2012). The first trimester 
gut microbiotas are like each other and comparable to that found in non-pregnant 
healthy women. By the third trimester, the between-subject diversity has 
significantly increased, even though within-subject diversity is decreased (Koren et 
al. 2012). Maternal stools show strong signs of inflammation in the third trimester, 
as concentrations of the pro-inflammatory cytokines are significantly higher than in 
the first trimester. When delivered into germ-free mice, third trimester microbiota 
caused a greater adiposity and insulin resistance than first trimester stools (Koren et 
al. 2012). Thus, the features common in the metabolic syndrome and type 2 diabetes, 
such as weight gain, dysbiosis and inflammation, are also central to normal 
pregnancy. Nevertheless, these features may be appropriate during pregnancy, as 
they promote energy storage in fat tissue and the growth of the fetus. However, the 
bacterial alterations in microbiota might also influence the mother’s metabolic 
profile and thus play a part in the development of pregnancy complications (Musso 
et al. 2010, Thum et al. 2012). For example, genera of Collinsella has been linked to 
obesity and insulin resistance (Gomez-Arango et al. 2016).  
There is some evidence which indicates that the microbiota composition differs 
between women who later develop GDM and those who remain healthy (Mokkala, 
Houttu et al. 2017). For example, the abundance of bacteria belonging to 
Ruminococcaceae family has been found to correlate with markers of glucose 
metabolism and GDM (Gomez-Arango et al. 2016, Mokkala, Houttu et al. 2017). 
Additionally, in women already diagnosed with GDM, the microbiota has been 
shown to be markedly altered in comparison to that in normoglycemic pregnant 
women in the third trimester (Crusell et al. 2018, Wang, J. et al. 2018). However, the 
conducted trials are relatively small and not all studies have detected differences in 
the microbiota between healthy women and women with GDM (Koren et al. 2012).  
Several randomized controlled trials have been conducted on administration of 
probiotics to prevent GDM, and these are presented in Table 3. Meta-analyses of these 
trials have yielded conflicting results on glucose metabolism, as one of them found 
that probiotics reduced fasting blood glucose, as well as serum insulin levels, HOMA-
IR and triglyceride levels (Han et al. 2019), while other meta-analyses showed only a 
significant reduction in serum insulin and HOMA-IR. (Jarde et al. 2018, Zheng et al. 
2018). In patients already diagnosed with GDM, several studies, mainly conducted on 
Asian populations, have reported benefits on glucose metabolism with a range of 
different probiotics (Dolatkhah et al. 2015, Karamali et al. 2016, Kijmanawat et al. 
2018), although there are also some trials detecting no benefits (Jafarnejad et al. 2016, 
Lindsay, K. L. et al. 2015). Meta-analyses have concluded that administration of 
probiotics in women with GDM can reduce insulin resistance but does not affect 
fasting blood glucose levels (Taylor et al. 2017, Zheng et al. 2018). 
  
Table 3. Randomized controlled trials on probiotics with information on glycemic control.  
Author Country Year Sample size Intervention Start/End Main outcome Result 
Laitinen et al., 
Luoto et al. 
Finland 2009 256 Lactobacillus rhamnosus GG 
(1010 cfu), Bifidobacterium lactis 
BB12 (1010 cfu) +/- dietary 
counselling 
I st trimester/ 
postpartum 
FPG FPG, Ins, HOMA-IR ↓ in 
probiotics vs. placebo. 
Incidence of GDM↓. 
Asemi et al. Iran 2013 70 Lactobacillus acidophilus LA5, 
Bifidobacterium animalis Bb12 
(total of min 107 cfu) 
3 rd trimester  
→ 9 weeks 
FPG, Insulin, 
HOMA-IR 
No difference in FPG. 
∆Ins and ∆HOMA-IR ↓ in 
probiotics vs placebo. 
Lindsay et al. Ireland 2014 175 obese 
women 
Lactobacillus salivarius 
UCC118 (109 cfu) 
24 gw/28 gw,  
4 weeks 
FPG No difference in FPG, Ins, 
HOMA-IR or incidence of 
GDM 
Jamilian et al. Iran 2016 60 Lactobacillus acidophilus, 
Lactobacillus casei, 
Bifidobacterium bifidum 
(2×109cfu) 
9 gw /21 gw ∆Ins No difference in FPG. ∆Ins, 
∆HOMA-IR, ∆trig., ∆hs-CRP ↓ 
in probiotics vs. placebo.  
Wickens et al. New 
Zealand 
(NZ) 
2017 373 L. rhamnosus HN001 6 × 109 
cfu 
14-16 gw / 
postpartum 
incidence of 
GDM 
GDM↓ in probiotics vs placebo 
with NZ OGTT criteria (no 
difference with IADPSG 
criteria except >35y and 
history of GDM). 
Okesene-Gafa 
et al. 
New 
Zealand 
2019 230 obese 
women 
Lactobacillus rhamnosus GG, 
Bifidobacterium lactis BB12 min 
6.5 x 109 cfu 
12-17+6 gw / 
birth 
GWG, 
birthweight 
No difference in FPG, OGTT, 
HbA1c or risk of GDM. 
Callaway et al. Australia 2019 411 
overweight 
and obese 
Lactobacillus rhamnosus 
(LGG), Bifidobacterium animalis 
subsp. lactis (BB-12) >1x109 cfu 
<20 gw / birth incidence of 
GDM 
No difference in incidence of 
GDM or OGTT 1h and 2 h. 
FPG ↑in probiotics vs placebo,  
Asgharian et 
al. 
Iran 2019 128 
overweight 
and obese 
Lactobacillus acidophilus La5, 
Bifidobacterium lactis BB12 5 × 
108 cfu/g 
24 gw / birth FPG, OGTT at 
28 gw 
FPG and 2h-OGTT ↓ in 
probiotics vs placebo. No 
difference in the incidence of 
GDM. 
Gestational diabetes (GDM), FPG= fasting plasma glucose, Ins=insulin, OGTT=oral glucose tolerance test, GWG=gestational weight gain, gw= 
gestational weeks. 
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2.3 Gestational weight gain (GWG) 
Although weight gain during gestation is an essential physiologic adaptation that 
promotes the development and growth of a fetus, both inadequate and excess GWG 
have been linked to adverse outcomes (Gilmore et al. 2015). Excessive GWG has 
been found to increase the risks of hypertensive disorders during pregnancy, GDM, 
Caesarean delivery, large for gestational age at birth, and overweight in the offspring 
(Gaillard et al. 2013, Santos et al. 2019). The preterm birth risk is higher in women 
gaining weight either inadequately or in excess (Santos et al. 2019). In a large 
epidemiological study, both extremities of GWG were discovered to have a higher 
association with infant death except that in women with BMI >40 kg/m2, GWG was 
no longer related to infant demise (Bodnar et al. 2016).  
To reduce the risks for maternal and offspring complications related to 
pregnancy, IOM has issued guidelines for GWG, which have been revised in 2009 
(Institute of Medicine 2009). These guidelines recommend less GWG for women in 
the higher BMI categories prior to pregnancy. Normal weight women are advised to 
gain weight 11.5–16 kg, overweight women 7–11.5 kg and obese women 5–9 kg 
(Figure 2).  
Over the last decades, GWG has markedly increased independent of 
prepregnancy BMI (Kinnunen et al. 2003). Only one third of pregnant women gain 
weight in accordance to IOM recommendations (Deputy et al. 2015, Devlieger et al. 
2016). Although overweight and obese women usually gain less weight than normal 
weight women, they are more often likely to exceed the GWG recommendations 
(Deputy et al. 2015). As obesity among reproductive women is very common, and 
obese mothers who gain weight in excess have a particularly high risk of different 
kinds of pregnancy complications (Santos et al. 2019), it is essential find means to 
maintain healthy GWG in pregnant women. 
Risk factors for excess GWG include maternal European ethnicity, nulliparity, 
high total energy intake, smoking during pregnancy, and high paternal BMI (Gaillard 
et al. 2013). Excess GWG occurring in the first trimester has been demonstrated to 
strongly predict excess GWG during the entire pregnancy in both normal weight and 
overweight/obese women (Knabl et al. 2014). 
Interventions to reduce excess GWG have yielded inconclusive results although 
these could be related to the intervention in question. The UPBEAT trial succeeded 
in reducing GWG with a combined lifestyle intervention (Poston et al. 2015), and 
two reviews have suggested that exercise-only interventions can reduce both total 
and excess GWG (Dipietro et al. 2019, Ruchat et al. 2018). In contrast, a very recent 
German multicenter trial found that lifestyle advice given by trained healthcare 
providers in the setting of routine prenatal care was not successful in reducing GWG 
or pregnancy complications (Kunath et al. 2019). 
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Figure 2.  Gestational weight gain recommendations based on prepregnancy BMI (Nelli study, 
UKK Institute for Health Promotion Research, Tampere, Finland). Adapted from 
recommendations issued by Institute of Medicine 2009.  
The impacts of excess GWG extend well beyond pregnancy as women who gain 
weight in excess, have more fat retention postpartum (Butte et al. 2003) and a greater 
risk of metabolic syndrome (Mamun et al. 2010, McClure et al. 2013). In summary, 
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GWG represents a major public health concern and more information is needed 
about ways to normalize GWG, especially in overweight and obese women. 
2.4 Body composition during pregnancy 
2.4.1 General principles 
Body composition provides much more precise information about the adiposity of 
the body than the more widely used BMI and reflects also nutritional intakes, losses 
and expenses over time (Lindsay, C. A. et al. 1997, Prentice and Jebb 2001). Obesity 
denotes accrual of excess body fat, and it is the amount of this excess fat that relates 
to health problems (Prentice and Jebb 2001). In contrast to body weight and BMI, 
methods for the assessment of body composition permit a measurement of tissue 
gains and losses.  
The human body can be divided into compartments at five different levels: 
atomic, molecular, cellular, tissue and whole-body levels (Wang, Z. M. et al. 1992). 
At the molecular level, body weight consists of FM and fat free mass (FFM), where 
FM is composed of nonessential lipids (90 % of total body lipids) and FFM is almost 
entirely constructed of water, protein, mineral and essential lipids (10 % of total body 
lipids) (Wang, Z. M. et al. 1992). 
In order to support the growth and development of the fetus and to prepare the 
mother for breastfeeding, the maternal body composition changes markedly during 
gestation. The GWG that reflects these changes, includes gains in maternal and fetal 
FM and FFM, as well as the placenta and amniotic fluid. There is marked inter-
individual variation especially in the FM gain during pregnancy, addressing the 
importance of measuring body composition (Marshall et al. 2016, Sewell et al. 
2007). During late pregnancy, BMI has been found to explain only 40% of the 
variance in BF% (Lindsay, C. A. et al. 1997). 
The measurement of body composition during pregnancy is challenging. The 
methods which have traditionally been used, cannot distinguish fetal from maternal 
tissues and handle the maternal-fetal dyad as a single unit. Another complicating 
factor is the enhanced hydration of FFM, which involves enlargement of the body 
water compartments. For example, total body water is enhanced during pregnancy 
by about 5–8 liters (Forsum et al. 1988, Kopp-Hoolihan et al. 1999, Lederman et al. 
1997). Thus, the composition of lean tissue changes across the pregnancy, a fact that 
must be accounted for in all body composition measurements based on FFM 
(Catalano, P. M. et al. 1995). 
It is acknowledged that age, diet, physical activity and chronic illness may 
influence body composition in humans that are not pregnant (Thibault et al. 2012). 
These same factors are probably also associated with body composition during 
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pregnancy, although less is known about features affecting gestational body 
composition. 
2.4.2 Measurement of body composition 
Body composition can be estimated at the same five levels from which the body is 
composed (Wang, Z. M. et al. 1992). Different components of the body can be 
measured either directly or indirectly, often applying the laws of physics in the 
calculations and exploiting the fact that certain stable proportions among the 
different components exist at the same level. There are no practical methods to 
measure body fat directly, thus indirect methods must be applied. This usually means 
that FFM is determined by measuring directly some component of it that forms a 
known proportion of FFM, and then FFM is subtracted from the total body weight 
to estimate the amount of fat (Wang, Z. M. et al. 1992). 
The measurement techniques of body composition can be categorized by the 
number of body compartments they determine (Elia 1992). Two compartment 
models (2C) divide the body into FM and FFM, where FFM constitutes of the 
combined mass of total body water (TBW), bone, protein, and mineral mass other 
than bone. In these models, a single measurement of one compartment permits 
calculation of the other by subtraction from body weight. More advanced models of 
the assessment of body composition that are also used in pregnant women, include 
3-compartment (3C) and 4-compartment (4C) models. They subdivide the FFM 
component into TBW and a combination of mineral and protein (3C), or into mineral, 
water and protein (4C-models). In addition, the 2C, 3C or 4C models cannot 
disentangle the maternal-fetal unit (Widen and Gallagher 2014). The 3C and 4C 
models are often composed by uniting parts of methods used in 2C models. Thus, 
although these models are often considered more precise than 2C models, they could 
bring about the propagation of any error created by its sub-methods.  
The IOM has stated that 2C, 3C and 4C models estimate gestational body 
composition changes with acceptable precision. The precondition is the use of 
corrected values for hydration and density of FFM (2C models), and for 3C and 4C 
models in which FFM hydration or density are measured (Institute of Medicine 
2009). Imaging techniques like magnetic resonance imaging (MRI) can assess 
specific organ volumes and may therefore allow an estimation of maternal and fetal 
deposits separately in the future (Most et al. 2018). A comparison of methods that 
measure body composition also during pregnancy is presented in table 4. 
 
  
Table 4. Methods that measure body composition. 2C/3C/4C= 2-, 3-, and 4 compartment models. Modified from Widen and Gallagher 2014. 
Method technique Advantages  Disadvantages Suitability in pregnancy 
Anthropometrics 
-skinfold 
thickness 
2C: FM and FFM estimated using 
validated equations 
Simple, rapid, cheap, 
information on regional 
distribution of fat 
Suitable for larger 
sample sizes 
Measurement 
subjective -
technician 
expertise required, 
less precise 
-Safe 
-Equations apply only for certain gestational 
ages 
-Pregnancy can alter compressibility of skinfold 
-Overestimates subcutaneous fat vs MRI 
-Edema can disturb measurements 
Total body 
water (TBW) 
2C: Stable isotope of water is 
ingested and it equilibrates within the 
TBW pool of the body. The size of 
the TBW pool determines the 
maximal concentration of the 
isotope. FFM is calculated with 
assumptions for the TBW: FFM ratio. 
Portable devices, 
can be used in 3C and 
4C models 
Laborious, takes 
4-5h, no 
information on 
regional 
distribution of fat 
-Safe 
-Hydration of FFM must be accounted for  
-Unable to disentangle maternal-fetal unit 
-requires fasting overnight + the 
measurement time 
Total body 
potassium 
(TBK) 
2C: the ratio of radioactive isotope 
potassium 40 (K40) found in 
human tissues and TBK is 
constant. Measurement of K40 
allows calculation of TBK. The 
known ratio of total body 
potassium to FFM allows 
determination of body composition. 
Can be used in 3C and 
4C to estimate protein 
Potassium 
concentration in 
FFM can vary. 
-Safe 
-Hydration of FFM must be accounted for  
-Unable to disentangle maternal-fetal unit 
-When used on 3C model (with TBW), no 
significant difference was detected compared 
to 4C model 
Underwater 
weighing 
2C: body volume is defined with 
Archimedes principle and used to 
calculate body density 
(weight/volume). Known densities 
of FM and FFM allows calculation 
of body composition. 
Noninvasive, precise, 
can be used in 3C/4C 
models 
Immersion under 
water can cause 
discomfort, no 
information on 
regional 
distribution of fat 
-Safe 
-Hydration of FFM must be accounted for 
-Unable to disentangle maternal-fetal unit 
Air 
displacement 
plethysmograhy 
2C: body volume is assessed with 
plethysmograph and used to 
calculate body density. Known 
densities of FM and FFM allows 
calculation of body composition. 
Rapid, well tolerated, 
can be used in 3C/4C 
models, suitable for 
larger sample sizes 
No information on 
regional 
distribution of fat 
-Safe 
-Hydration of FFM must be accounted for  
-Unable to disentangle maternal-fetal unit 
-Performs well compared to 3C/4C models 
(continued) 
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Table 4.  Continued. 
Method technique Advantages  Disadvantages Suitability in pregnancy 
BIoimpedance 2C: The opposition of the electrical 
flow by tissues allows for 
estimation of total body water from 
which estimates of FM and FFM 
can be derived.  
rapid, cheap, 
noninvasive, well 
tolerated, suitable for 
larger sample sizes 
Accuracy 
Not validated for 
regional 
distribution of fat 
-Safe 
-Unable to disentangle maternal-fetal unit 
-BIA may underestimate total body water 
-Additional validation studies needed 
Dual-energy X-
ray 
absorptiometry 
(DXA) 
3C/4C: Two X-ray beams, with 
different energy levels, are aimed 
at the patient's bones to measure 
bone mineral content, FFM and 
FM. 
Well tolerated, gives 
information on regional 
fat distribution, practical, 
precise, suitable for 
larger sample sizes 
Hydration of 
tissues affects 
results 
-Not suitable due to radiation exposure 
-Used just before/after pregnancy as a part of 
3C/4C models 
- Bone mineral density is decreased during 
late gestation and during lactation and this 
could affect the accuracy. 
ultrasound Based on production of sound 
waves at changing frequencies to 
measure adipose tissue depot  
Well tolerated, cheap, 
information on regional 
fat distribution, suitable 
for larger sample sizes 
Measures only 
regional- not 
whole-body fat 
distribution, 
compressibility of 
the skin may vary 
and cause error 
-Safe 
-Standardized measurement locations 
difficult to achieve 
-Uterine contents can be separated from 
maternal tissues 
-Not validated against MRI 
MRI Area estimates of fat can be 
achieved. These can be 
transformed into volume measures 
if the distance between slices is 
accounted for.  
Precise, well tolerated, 
noninvasive, gives 
information on regional 
fat distribution. validated 
against phantoms and 
cadaver body 
composition 
Expensive, 
complicated, 
laborious, requires 
technician 
expertise and time  
- Safety at 1st trim. has not been sufficiently 
evaluated 
- Standardized measurement locations 
difficult to achieve when regional fat is 
evaluated 
-Uterine contents can be separated from 
maternal tissues 
-Discomfort possible especially for 
overweight and obese women 
- No publications reporting the use of MRI to 
evaluate changes in body composition 
throughout pregnancy 
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2.4.2.1 Air displacement plethysmography 
Air displacement plethysmography (ADP), a 2C method, utilizes densitometric 
principles of lean soft-tissues and fat to estimate FM and FFM.  
Plethysmography refers to the measurement of size, usually volume. In ADP, 
body volume is measured indirectly by determining the volume of air that the body 
displaces inside an enclosed chamber (plethysmograph). Body volume can be 
calculated with subtraction of the volume of air outside the body in chamber from 
the air volume of an empty chamber (Fields et al. 2002). ADP device constitutes of 
two chambers, one 450-liter chamber where the subject sits, and a reference chamber 
of 300 liters (Dempster and Aitkens 1995, McCrory et al. 1995) (Figure 3). A 
diaphragm oscillates between the chambers, creating volume changes that cause tiny 
pressure alterations, which are monitored by transducers and analyzed for pressure. 
The test chamber volume is measured as a ratio of these pressures (Fields et al. 2002), 
as is described by Poisson’s Law. 
 
Figure 3.  Air displacement plethysmography for measuring body composition (the Bod Pod 
system, COSMED, Inc., Concord, CA, USA). 
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However, there is some volume of isothermal air that is contained in the lungs, near 
to skin or hair, and in clothing that must be accounted for in the calculations of body 
composition with ADP (Fields et al. 2002). To minimize the error, the subjects are 
asked to wear tight underwear and a cap, and additionally, a surface area artifact is 
calculated. The isothermal air in the lungs is considered by either measurement or 
prediction of thoracic gas volume (TGV). 
The results of a previous small study in normal-weight women indicate that the 
prediction of TGV compared to its measurement leads to an overestimation of BF% 
by 0.5% at 32 weeks of gestation (Henriksson et al. 2013). Loss and gain of weight 
have also been discovered to affect the measured TGV in non-pregnant overweight 
women (Minderico et al. 2008). Nevertheless, recent trials have used predicted TGV 
in defining FM during pregnancy (Henriksson et al. 2015, Svensson et al. 2016). As 
both the growing uterus and high BMI might influence the estimation of TGV during 
gestation, the measurement of TGV could provide more precise estimations of body 
composition, particularly in pregnant women in upper BMI categories. As explained 
by Fields et al. (2002), it is important to correct the body volume estimate for the 
average amount of air in the lungs during normal breathing.  Thus, the Bod Pod 
device determines TGV at mid-tidal exhalation.  When the TGV is measured, the 
subject breathes through a disposable tube while wearing a nose clip. The subject is 
asked to first breathe normally and later to make a couple of gentle puffs by 
interchangeably contracting and relaxing the diaphragm. This causes slight changes 
in the gas volume of the airways, simultaneously with alterations in body volume 
that are equal but opposite. These volume alterations create pressure changes that are 
monitored. A comparison of the magnitudes of the changes in airway and chamber 
pressure allows calculation of TGV (Fields et al. 2002). 
Once the body volume and weight have been measured, body density is 
determined from the ratio of body mass to volume, from which FM and FFM can be 
estimated combining the assumed respective densities for FM and FFM. In the 
calculations, it is important to consider the enhanced hydration of FFM caused by 
pregnancy. Van Raaij et al. (1988) have provided estimates of FFM densities over 
the course of pregnancy that consider the physiological changes and contribution of 
the products of conception to the composition of the pregnant body. As a result, the 
IOM has stated that 2C, 3C and 4C models estimate gestational body composition 
changes with acceptable precision (Institute of Medicine 2009).  
ADP has been considered as a good method to measure adiposity in overweight 
and obese non-pregnant women (Wingfield et al. 2014). In the study of Marshall et 
al. (2016), body composition of pregnant women at term was determined with 2-, 3- 
and 4-compartment models and compared with measurements with dual-energy X-
ray absorptiometry (DXA) 2 weeks postpartum. It was discovered that ADP was well 
accepted in late gestation and, with the use of the Van Raaij equation based on 
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gestational age (van Raaij et al. 1988), provided the most precise estimate of 
maternal FM compared with postpartum DXA. The limitations of ADP, like many 
other methods except imaging techniques, include the failure of measuring the intra-
abdominal and visceral fat separately and the inability to differentiate fetal tissues 
from maternal tissues (Widen and Gallagher 2014). These limitations can be 
overcome, at least to some extent, by assessing change in sufficiently many subjects 
and thus minimizing the effect of bias due to the measurement method and the effect 
of possible individual variation related to results.   
For these reasons, and the fact that ADP is rapid, suitable for larger sample sizes, 
and well accepted by the pregnant women, ADP was chosen to measure maternal 
body composition in the studies included in this thesis. 
2.4.3 Physiological changes during pregnancy 
Maternal body composition changes are reflected in the accrual of protein, fat, water, 
and minerals that are deposited in the fetus, placenta, amniotic fluid, uterus, 
mammary gland, blood, and adipose tissue (Pitkin 1976). In early pregnancy, smaller 
changes in maternal FM and FFM occur compared to the larger and variable changes 
in FM and FFM detected in late pregnancy caused by the growing fetal unit (Institute 
of Medicine 2009). The IOM also states that it is not completely understood the 
extent to which the changes in body composition, and particularly in FM, are critical 
for normal fetal development or are incidental to pregnancy.  
The uterine contents (the placenta, fetus and amniotic fluid) constitute about one 
third of the total GWG at term (Pitkin 1976). At birth, the BF% of human fetus is 
roughly 12–16%, corresponding to around average 350g of FM (Catalano, P. M. et 
al. 2003). Most of this fat is accrued in late pregnancy (Eriksson et al. 2011). The 
rest (84–88%) of fetus is FFM, of which approximately 80% is water. The placenta 
consists of 88% water, 11% protein, and only 1% fat (Widdowson and Spray 1951). 
The volume of amniotic fluid varies widely between pregnancies but is rather stable 
from 22 to 39 gestational weeks with the mean of 800 ml (Brace and Wolf 1989). 
Thus, it contributes markedly to the increased water accumulation during pregnancy.  
Less than 1 kg of protein is accrued in the body during gestation, and 
predominantly in late pregnancy (Butte et al. 2003, Forsum et al. 1988, Pipe et al. 
1979). Protein is deposited mainly in the fetus (42%), but also in the uterus (17%), 
blood (14%), placenta (10%), and breasts (8%) (Hytten, F. and Chamberlain 1991).  
TBW accrual in FFM is largely hormonally regulated during pregnancy (Institute 
of Medicine 2009). The accumulation has been found to average about 7-8 liters in 
uncomplicated pregnancies (Hytten, F. E. et al. 1966) and it has not been found to 
differ systematically among the underweight, normal weight or obese women 
(Lederman et al. 1997). The large proportion of water accrued relative to GWG leads 
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to enhanced hydration of FFM throughout pregnancy (Hytten, F. E. et al. 1966, van 
Raaij et al. 1988). 
On average, GWG is 42% FM and 58% FFM (Butte et al. 2003), although there 
is a marked individual variation. Whereas GWG is positively associated with the 
gain in FM, FFM gain is rather constant between pregnancies. As with GWG, the 
FM gain during pregnancy is inversely correlated with prepregnancy BMI. Among 
women who gain weight in accordance to IOM recommendations, changes in FFM 
seem to be rather consistent and independent of BMI. Thus, lesser GWG among 
obese women is almost completely accounted for by a lesser gain in FM (Lederman 
et al. 1997). 
In studies conducted with MRI, Sohlstrom and Forsum (1995) discovered that 
three fourths of FM gain were deposited subcutaneously during gestation, 
resembling the fat distribution before pregnancy. During gestation, 68% of the 
increased adipose tissue volume was in the trunk and 16% in the thighs. However, 
there is inter-individual variation in the site where fat is stored (Larciprete et al. 
2003). Obese women with larger deposits of subcutaneous fat prior to pregnancy 
tend to accrue FM in visceral depots more than normal weight women over 
pregnancy (Ehrenberg et al. 2003, Sohlstrom et al. 1993). FM gain has also been 
shown to correlate positively with postpartum weight retention (Butte et al. 2003). 
Moreover, it is known that FM accrual in visceral depots and around the central 
organs is correlated with insulin resistance, cardiovascular disease risk, and 
metabolic syndrome (Despres 2006).  
It has to be recognized that in most studies on gestational body composition, the 
participating women have had normal prepregnancy BMI, and thus studies with 
longitudinal changes in FM in overweight and obese women are lacking (Institute of 
Medicine 2009, Most et al. 2018). 
2.4.4 Impact of lifestyle on maternal body composition 
Physical activity has been found to reduce GWG and in some studies, also improve 
blood glucose concentration and prevent GDM (Davenport et al. 2018, Ruchat et al. 
2018). However, the impact of physical activity on body composition of pregnant 
women is largely unknown. It is known that women reduce physical activity 
markedly during pregnancy (Amezcua-Prieto et al. 2013, Evenson and Wen 2011) 
and less than half of the women adhere to the physical activity guidelines (Most, 
Dervis et al. 2019). Along with energy consumed, the reduction of physical activity 
could have an influence on maternal FM accrual. 
Although the relationship between energy intake and GWG has been studied, 
there is little information in the literature concerning the association of body 
composition with energy intake during pregnancy. It has been found that pregnant 
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women may increase their BF% without any significant change in energy intake and 
even with the increase in total energy expenditure (Abeysekera et al. 2016). The 
authors suggested that pregnancy alters homeostatic mechanisms, allowing for a 
more efficient fat storing state mediated by factors additional to those controlling 
metabolism in the non-pregnant state. However, the reliability of methods assessing 
energy intake (self-reported food diaries) have been questioned, suggesting that there 
could be inconsistencies between reported and actual energy intake (Dhurandhar et 
al. 2015). 
Regarding energy intake, Most et al. (2019) have stated that in order to stay 
within IOM GWG recommendations, obese women must lose 2.5 kg FM and their 
energy intake should be less than energy expenditure. In their study, the ideal GWG 
was accomplished by the gain of FFM alone. The consumption of energy of obese 
pregnant women staying within IOM recommendations did not increase after early 
pregnancy. Most et al. suggested that the energy demands of the pregnant body with 
the fetal unit is compensated for by the utilization of maternal FM. It was also 
proposed that it is the energy imbalance that regulates GWG, and not the diet quality 
or physical activity. No adverse effects on maternal or fetal outcomes were detected 
in the group of women with inadequate GWG but it was acknowledged that the 
sample size was too small to reliably assess these outcomes. In two previous studies, 
weight loss or GWG< 5kg has been associated with significantly increased risks of 
small for gestational age infants (Blomberg 2011, Catalano, P. M. et al. 2014). These 
neonates had also less FM, FFM and a smaller head circumference (Catalano, P. M. 
et al. 2014), which could be associated with further increases in the metabolic and 
cognitive risk for the offspring through adaptive processes in utero and programming 
of health (Catalano, P. M. et al. 2014, Dewey and Begum 2011). 
Other lifestyle factors that could affect body composition include some 
nutritional supplements. The consumption of n-3 LC-PUFA has been suggested to 
modestly reduce weight and BF% in non-pregnant individuals (Bender et al. 2014). 
In animal models, evidence indicates a role for n-3 LC-PUFAs in reducing FM 
(Albracht-Schulte et al. 2018). The literature also indicates that probiotics may help 
to reduce weight and FM in overweight adults, especially certain strains of 
Lactobacillus and Bifidobacterium (Borgeraas et al. 2018, Crovesy et al. 2017). The 
effects of both n-3 LC-PUFA and probiotics on GWG and body composition during 
pregnancy are largely unknown. 
All in all, more information is needed regarding the association of lifestyle 
factors such as physical activity, dietary intake and diet quality with body 
composition in pregnant women especially in the upper BMI categories. 
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2.4.5 Body composition of women with GDM 
Although GDM is associated with adiposity, mainly defined as high prepregnancy 
BMI, little is known about the actual body composition of women diagnosed with 
GDM. A few studies have evaluated the possibility of early pregnancy body 
composition to predict the development of GDM. These studies suggest that 
ultrasonographically measured visceral fat thickness is associated with GDM or 
higher glucose values (Bartha et al. 2007, De Souza et al. 2016, Gur et al. 2014, 
Martin, A. et al. 2001). As this is an area with a paucity of literature, further studies 
are needed to elucidate the impact of GDM on maternal body composition. 
2.5 Summary of the literature 
As the prevalences of obesity and GDM are rising, it is essential to find new and 
more efficient means to prevent GDM, reduce maternal adiposity and to enable 
GWG within recommendations. There is some indication that probiotics and fish oil 
could exert beneficial effects on glucose control and insulin resistance, but the 
literature in pregnant women regarding this topic is scanty. As n-3 LC-PUFA and 
probiotics have immunomodulatory effects and both improve gut barrier integrity, 
they could also potentially have synergetic effects on the morbidities related to 
chronic low-grade inflammation and insulin resistance, such as GDM. However, no 
studies on this subject exist in pregnant women. Further, knowledge related to the 
factors that influence body composition of overweight and obese pregnant women is 
limited, and more information is needed to enable development of more efficient 
means to improve maternal body composition and possibly prevent the pregnancy 
complications associated with increased adiposity. Surprisingly, as GDM is a 
common condition, the literature concerning the body composition of women with 
GDM is almost nonexistent. The studies in this thesis were targeted to fill in these 
gaps in the literature and to provide new means to prevent GDM. 
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3 Aims 
The objective of this study was to evaluate in a randomized, placebo-controlled trial, 
the effects of fish oil and probiotic intervention on glucose metabolism and body 
composition in overweight and obese pregnant women. Additionally, the purpose of 
this thesis was to characterize the determinants of maternal body composition. 
 
The specific aims were to investigate in overweight and obese women: 
1. If an intervention with fish oil and/or probiotics decreases the risk of GDM, 
fasting glucose concentrations, and insulin resistance, and if it influences GWG 
and maternal body composition (Studies I and II).  
2. Whether a GDM diagnosis affects the accrual of FM during pregnancy, and 
whether body composition in early pregnancy predicts the development of GDM 
at approximately 24–28 gestational weeks (Study II). 
3. If energy intake, energy yielding nutrients, diet quality and physical activity 
associate with maternal body composition, and how inadequate, appropriate and 
excess GWG relate to body composition changes during pregnancy (Study III). 
4. Whether the measured TGV differs significantly from predicted TGV in 
pregnant women and whether the possible difference affects to any significant 
extent the calculations of body composition (Study IV). 
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4 Materials and Methods 
4.1 Study design, randomization and subject 
characteristics 
4.1.1 Study design 
A double-blind, randomized trial on the effects of fish oil and/or probiotic food 
supplements on maternal and child health was conducted. This single-center trial 
was executed in the University of Turku and Turku University Hospital in Finland 
with recruitment between October 2013 and July 2017 (ClinicalTrials.gov Identifier: 
NCT01922791). The study complies with the Declaration of Helsinki. The Ethics 
Committee of the Hospital District of Southwest Finland approved the study protocol 
and all participants provided written informed consent. 
4.1.2 Recruitment and randomization 
Leaflets with the study information were distributed in maternal welfare clinics. 
Furthermore, media and social media were used to inform about the study. Those 
women willing to participate in the study contacted the project coordinator for 
further information and to schedule their first study visit. Eligible women were 
randomly assigned to one of the four parallel groups at the first study visit in early 
pregnancy: fish oil+placebo (i.e. placebo for probiotics), probiotics+placebo (i.e. 
placebo for fish oil), fish oil+probiotics or placebo+placebo (placebo for probiotics 
and placebo for fish oil). Subjects were allocated into intervention groups according 
to the mother’s parity and their history of GDM (primipara; multipara; multipara 
with previous GDM). The stratified randomization was performed with random 
permuted blocks of 4, and randomization lists of the three blocks were generated by 
a statistician who was not involved in either study recruitment or its execution. 
Women were assigned to the intervention groups according to the randomization list 
in their order of recruitment on the first study visit. The staff responsible for 
enrollment of participants, study visits and assessing outcomes remained blinded to 
the intervention, as were the participants. 
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4.1.3 Participants 
A total of 988 women from Southwest Finland were screened for eligibility and 439 
women were randomized to the intervention (Figure 4). The study was discontinued 
by 39 (8.9%) women before the OGTT and altogether by 59 (13.5%) women before 
the late pregnancy study visit. A few test results were unavailable because of failure 
to fast before blood tests (n=4) or interruption of the OGTT (n=2) or giving birth 
prematurely (n=6). 
 
Figure 4. Flow diagram of the study. Modified from Pellonperä et al., studies I and II. 
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In studies III and IV, the data from 110 women that were the first to recruit and 
whose body composition was measured at the two visits during the pregnancy was 
utilized. In studies I and II, the available data collected from all the recruited women 
was utilized. The inclusion criteria of the study were: self-reported prepregnancy 
BMI≥25 kg/m2, less than 18 gestational weeks and absence of chronic diseases 
(asthma and allergies were allowed). Exclusion criteria were: pregestational diabetes 
(HbA1c ≥6.5% [48 mmol/mol] or fasting glucose ≥7.0 mmol/l at randomization); 
multifetal pregnancy; chronic diseases impacting on metabolic and gastrointestinal 
health including inflammatory bowel diseases; refusal to terminate the intake of 
other probiotic or fish oil supplements; diagnosis or history of coagulopathy; use of 
anticoagulants. 
4.2 Study conduct 
Women attended two study visits during gestation (mean 13.9±2.1 and 35.2±0.9 
gestational weeks). On the first study visit, height was measured with a wall 
stadiometer to the nearest 0.1cm. Prepregnancy BMI was calculated using height and 
self-reported prepregnancy weight obtained from the maternal welfare clinic records. 
Weight, body composition and blood pressure were measured on both visits and 
blood samples were obtained.  
Women filled in questionnaires and were interviewed concerning their health, 
education, smoking habits, obstetric medical history and family history of diabetes. 
Questionnaires concerning physical activity and dietary quality were filled in. 
Furthermore, three-day food diaries were recorded during the week preceding the 
study visits. During the intervention period, women were asked to keep a diary on a 
weekly basis to report possible adverse effects related to supplement consumption. 
Data on pregnancy and delivery were collected from hospital medical records. 
4.3 Food supplements 
Food supplements were provided from the first study visit, throughout the pregnancy 
and until 6 months postpartum. Women were advised to take two fish oil capsules 
and one probiotic capsule daily. The stability of the supplements was monitored by 
both manufacturers regularly during the trial. All capsules were identically packaged 
and identified by trial codes. Women were asked not to consume any other probiotic 
and n-3 LC-PUFA or other oil products during the study. 
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4.3.1 Fish oil supplements 
The fish oil capsules (Croda Europe Ltd., Leek, UK) contained a total of 2.4 g of n-
3 fatty acids, of which 79% (1.9 g) DHA (22:6 n-3,) and 9.4% (0.22 g) EPA (20:5 
n-3,), the rest being other n-3 fatty acids including docosapentaenoic acid. Placebo 
capsules for fish oil contained an equal amount of medium-chain fatty acids (capric 
acid C8 54.6% and caprylic acid C10 40.3%) and were of the same size, shape, color 
and lemon flavor as the fish oil capsules. The oil capsules were stored at room 
temperature. 
4.3.2 Probiotic supplements 
Probiotic capsules contained Lactobacillus rhamnosus HN001 (ATCC SD5675; 
Dupont, Niebüll, Germany) and Bifidobacterium animalis ssp. lactis 420 (DSM 
22089; Dupont, Niebüll, Germany), each 1010 CFU per capsule. Placebo for the 
probiotics consisted of microcrystalline cellulose; the capsules were identical to the 
probiotic capsules in size, shape, and color. Capsules were stored at -20°C until 
provided to the subjects, who were instructed to store the capsules in a refrigerator. 
4.3.3 Compliance 
Compliance with the consumption of capsules was assessed first by a phone call at 
mean 28 gestational weeks, subsequently by interview at the second study visit (good 
compliance being defined as taking study capsules ≥5 days/week reported at both 
time points), and thirdly, by counting the numbers of consumed fish oil capsules i.e. 
subtracting the capsules returned to the study unit from the total provided by a 
random sample of 62 women (14% of participants). 
4.4 Diagnosis and management of GDM 
GDM was diagnosed based on a 2-hour 75 g OGTT if one or more values were at or 
above the threshold level: 0h ≥5.3, 1h ≥10.0, 2h ≥8.6mmol/l according to the Finnish 
Current Care guidelines (Finnish Current Care guidelines for gestational diabetes 
2013). OGTT was offered by maternal welfare clinics to all women between 24–28 
gestational weeks and to high-risk women also at 12–16 gestational weeks 
(BMI≥35 kg/m2, previous GDM, glucosuria, polycystic ovary syndrome or family 
risk of diabetes). We used also the diagnostic criteria from the IADPSG with the 
following diagnostic thresholds: 0h ≥5.1, 1h ≥10.0, 2h ≥8.5 mmol/l. Regardless of 
the timing of OGTT, treatment for GDM was offered soon after diagnosis by health 
care services independent of the research protocol and in accordance with the 
national guidelines. 
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4.5 Blood sampling and analysis 
On the morning of each study visit, after at least 9-hours of overnight fasting, blood 
samples were drawn from an antecubital vein. A certified laboratory (TYKSLAB, 
the Hospital District of Southwest Finland) was used for the sampling, with analyses 
of glucose and insulin conducted by an enzymatic method utilizing hexokinase and 
by immunoelectrochemiluminometric assay, respectively. Insulin resistance was 
assessed by calculating HOMA2-IR from fasting glucose and insulin concentrations 
(Wallace et al. 2004). 
4.6 Body composition and gestational weight gain 
4.6.1 Determination of maternal body composition 
On both study visits, ADP and an electronic scale (the Bod Pod system, software 
version 5.4.0, COSMED, Inc., Concord, CA, USA) were applied to define the weight 
and the volume of the body according to the manufacturer’s instructions. FM and 
FFM in kilograms were calculated from density using the formulas devised by van 
Raaij et al. (van Raaij et al. 1989), which consider the gestational age and the 
presence of marked general swelling if necessary. When possible, TGV was 
measured (n=385/438 in early pregnancy and n=341/369 in late pregnancy) and used 
in the calculations of FM and FFM, otherwise predicted TGV was used. Women 
were asked to fast overnight, wear a tight cap and tight underwear and empty their 
bladder before the measurement of body composition. They were also advised to 
avoid exercise and showering in the morning of measurements. 
4.6.2 GWG 
Women were classified into groups of excess, appropriate and inadequate GWG 
according to the recommendations issued by the IOM (Institute of Medicine 2009). 
We assessed 1) the weight gain during the pregnancy and 2) weekly weight gain rate. 
1) Weight gain during the whole pregnancy was calculated as a difference of the 
last measured weight in the third trimester (either at maternity welfare clinic or at 
the second study visit, whichever visit was the latest) and self-reported prepregnancy 
weight. This weight gain was compared to IOM recommendations issued for 
overweight and obese women.  
2) In study III, the actual measured weight gain between the visits was compared 
to recommended minimum and maximum weight gains considering the gestational 
age and the recommended weight gain between the two visits. The IOM 
recommendation assumes a weight gain of 0.5–2 kg in the first trimester for all 
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women, and during the 2nd and the 3rd trimesters, overweight women (pre-
pregnancy BMI 25.0–29.9 kg m-2) are recommended to gain 0.23–0.33 kg per week 
and obese women (pre-pregnancy BMI≥30.0 kg m-2) 0.17–0.27 kg per week 
(Institute of Medicine 2009). Enrollment of some women in the first trimester (i.e. ≤ 
13+0 gestational weeks) was considered by multiplying the proportion of gestational 
weeks that was left from the first trimester with either 0.5 kg (recommended 
minimum) or 2.0 kg (recommended maximum) and by adding these first trimester 
weight gains respectively to recommended minimum or maximum weight gains 
during the 2nd and 3rd trimesters of pregnancy.   
In study II, we used the same method as described above to assess the weight 
gain, but additionally, we also categorized the weekly GWG rate between the first 
study visit and the last gestational weight measurement. 
4.7 Lifestyle 
4.7.1 Total energy and energy yielding nutrients 
Women were asked to keep a food diary over 2 weekdays and 1 weekend day in 
three consecutive days during the week preceding the study visits. They were given 
oral and written instructions on how to fill in the food diary and diaries were checked 
by the research personnel for completeness and accuracy with the help of an 
illustrated portion booklet. Mean daily intakes of energy (megajoules) and energy 
yielding nutrients (grams and percentage of energy intake, E%) were calculated by 
using computerized software (AivoDiet 2.0.2.3;Aivo, Turku, Finland) utilizing the 
food composition database provided by the Finnish National Institute for Health and 
Welfare (www.fineli.fi). 
4.7.2 The quality of diet 
IDQ (index of diet quality) questionnaire was used to evaluate the quality of overall 
diet on both study visits (Leppala et al. 2010). This validated questionnaire consists 
of several questions concentrating on the frequency and amount of consumption of 
certain food products during the preceding week. The health promoting criteria 
included the following: use of wholegrain bread (≥4 slices/per day), 
saturated/unsaturated fatty acids (vegetable oil-based margarine on bread, fish at 
least twice a week, use of low-fat ≤1% dairy products), dairy products (at least 4 dl/ 
day), consumption of vegetables, fruits and berries (≥400 g/day), and use of sugar 
containing drinks and sweets, and less than 2 skipped meals/week. The quality of the 
diet was defined as poor when index points were <10/15 and good when points were 
≥ 10/15 (Leppala et al. 2010). 
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4.7.3 Physical activity 
Physical activity was evaluated with a questionnaire (Mansikkaniemi et al. 2012). 
Subjects were requested to report the intensity, frequency and duration of their 
habitual leisure-time physical activity during the preceding week. A metabolic 
equivalent index for leisure-time physical activity (MET-index) was calculated from 
the product of intensity x frequency x duration of activity (MET h/wk) on both study 
visits. The coefficients for the intensity of physical activity were estimated from the 
existing tables (Ainsworth et al. 1993). 
4.8 Fetal weight and the amount of amniotic fluid 
Fetal weight was estimated ultrasonographically (Medison Accuvix XQ, Seoul, 
South Korea) in late pregnancy (35.3±1.1 gestational weeks) by determining fetal 
abdominal circumference, femur diaphysis length and biparietal diameter and 
applying the Hadlock II formula (Hadlock et al. 1985). The amount of amniotic fluid 
was estimated by measuring the amniotic fluid index (AFI), which involves 
summing the deepest vertical pockets in each of four quadrants of the uterus (Phelan 
et al. 1987). 
4.9 Power calculations and statistical analyses 
4.9.1 Power calculations 
In this trial, power calculations were executed for the primary outcomes of study I, 
i.e. the incidence of GDM based on the OGTT result targeted at 24–28 weeks of 
gestation and the change in fasting plasma glucose between the early and late 
pregnancy study visits. The sample size was calculated on the basis of the main 
outcome variables (power of 80% and significance level p<0.05). Based on a 20% 
reduction in the incidence of GDM in the fish oil or probiotic group from 50% to 
30% (Chu et al. 2007, Luoto et al. 2010) and a further 5% decrease in the combined 
intervention group (from 50% to 25%), a sample size of 93 per group was estimated. 
For fasting plasma glucose levels, a sample size of 50 subjects per group was 
calculated in order to detect a treatment effect of -0.2 mmol/l in glucose assuming 
that the standard deviation was 0.35 (Laitinen et al. 2009). We aimed to recruit 440 
volunteers to the study (110 in each intervention group), allowing for 20% dropout. 
Prespecified secondary outcomes without power calculations included the 
change in insulin and HOMA2-IR-values, the need for medication in the 
management of GDM (insulin or metformin), maternal body composition and GWG. 
Materials and Methods 
 49 
4.9.2 Statistical analyses 
In all studies, the normality of the data was checked visually from histograms. The 
data were summarized as frequencies and percentages for categorical variables and 
as means and standard deviations for normally distributed continuous variables. For 
non-normally distributed variables, medians and interquartile ranges were utilized.  
In cases where differences were reported, 95% confidence intervals were calculated. 
Statistical significance was set at p-value<0.05. Analyses were performed using 
either SAS software (version 9.4, SAS Institute Inc., Cary, NC, studies I and II) or 
with IBM SPSS statistics version 22.0 for Windows (IBM SPSS Inc. USA, Chicago, 
IL, USA, studies III and IV). 
4.9.2.1 Study I 
Our analysis was by intention to treat. The comparisons of baseline characteristics, 
OGTT-test result, GDM diagnosis and maternal/neonatal outcomes among the 
intervention groups were conducted by one-way ANOVA for continuous variables 
and χ2 test or Fisher’s exact test for categorical variables, when applicable. 
Differences in the change of glucose, insulin and HOMA2-IR were also compared 
with one-way ANOVA. General Linear models with binomial distribution and log 
link function was used to compare the relative risk of GDM in each intervention 
group with the placebo+placebo group. The modifying effect of potential 
confounding factors on the effect of the intervention (confounding factor×group 
interaction effect) on the incidence of new GDM diagnoses was analyzed using the 
generalized linear model. Two-way ANOVA was used to analyze the modifying 
effect of potential confounding factors on the effect of the intervention (confounding 
factor×group interaction effect) on the change in fasting plasma glucose, insulin and 
HOMA2-IR. Again, we used χ2 test or Fisher’s exact test to compare differences 
among the intervention groups with respect to compliance, number of women 
discontinuing the study and adverse effects. The comparison of duration of the side 
effects and postpartum hemorrhage between the intervention groups was conducted 
with the nonparametric Kruskal-Wallis test. 
4.9.2.2 Study II 
The comparisons of baseline characteristics among the intervention groups as well 
as the effect of the intervention on GWG and body composition were conducted by 
one-way ANOVA for continuous variables and χ2 test or Fisher’s exact test for 
categorical variables, when applicable. 
The energy consumption among the intervention groups was compared with one-
way ANOVA. Physical activity was measured with the MET-index, which was not 
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normally distributed and hence, the median with interquartile range was calculated 
and Kruskal-Wallis test applied when the intervention groups were compared. 
GDM and non-GDM women were compared at baseline with two-sample t-test, 
χ2 test or Fisher’s exact test, when applicable. When GWG and body composition 
between GDM women and non-GDM women were compared, for continuous 
variables we used two-sample t-test and a linear model adjusted for variables that 
differed between the groups significantly at baseline and that were significantly 
associated with the measured outcome. Likewise, categorical variables were 
analyzed with χ2 test and, in addition, with logistic regression adjusted for 
confounding variables. As a result, adjustments were made for age, prepregnancy 
BMI, previous GDM, intervention group and for the GWG analyses, also for 
gestational weeks at the last weight measurement.  
Possible correlations between lifestyle variables and changes in body 
composition measures in all women, in women with GDM and in normoglycemic 
women, were assessed using partial Pearson’s correlation test. Correlations of at least 
a medium effect size (r≥0.3) were considered meaningful (Cohen 1992). 
4.9.2.3 Study III 
Paired samples t-test was applied to calculate the change between early and late 
gestation in body composition variables or daily energy/macronutrient intakes. 
Wilcoxon signed ranks test was used to assess the potential changes in physical 
activity (MET-index). When comparing the differences in body composition 
between women with inadequate, appropriate or excess weight gain, we used one-
way ANOVA with Games-Howell post-hoc tests. When comparisons of energy 
intake, IDQ- or MET-indices were made between subgroups of different GWG and 
BMI categories, one-way ANOVA and independent samples t-test were applied for 
normally distributed data and Mann Whitney and Kruskall-Wallis tests for non-
normally distributed data.  
Possible correlations between lifestyle variables or ultrasound measurements and 
body composition measures (outcome variables) were assessed using partial 
Pearson’s correlation test adjusting for gestational age and pre-pregnancy BMI. In 
adjustments, gestational age at the point of measurement of each variable were used 
and when the change was evaluated, we also adjusted for weeks between early and 
late gestation visits. Associations between MET-index and body composition 
(outcome variable) were assessed with Spearman’s correlation test without 
adjustments, since no correlation between body composition variables and 
gestational weeks or pre-pregnancy BMI existed. Correlations of at least medium 
effect size (r≥0.3) were reported (Cohen 1992). We also conducted linear models 
assessing the relationship between explanatory lifestyle variables (physical activity, 
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dietary quality and macronutrient intake) and the change in either FM, FFM or BF% 
(outcome variables). We adjusted all models for intervention group, gestational 
weeks at enrollment, age, height, and for each early gestation body composition 
variable. 
4.9.2.4 Study I V 
In the comparisons, paired samples t-test was used to calculate the difference in 
measured TGV between early and late gestation and to estimate differences between 
measured and predicted TGV in body composition results at both time points.
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5 Results 
5.1 Characteristics of women 
A high compliance rate related to the intervention was reported by 88.4% of the 
women with this number being similar in the four intervention groups (p>0.98, data 
not shown). The compliance calculated from the returned fish oil capsules indicated 
that a mean of 91.8% (SD 15.9) of the capsules had been consumed. 
The clinical characteristics of the women at baseline are presented in Table 5. 
Baseline characteristics did not differ among the intervention groups, except for a 
family history of diabetes that was more common in women in the fish oil+placebo 
group as compared to the probiotics+placebo and placebo+placebo groups 
(p=0.012). Women participating in the study were generally in good health, although 
some mild medical conditions including allergy and/or atopy (20.5% of the women), 
asthma (8.8%), migraine (8.8%) and hypothyroidism (7.0%) were reported (all non-
significant between the intervention groups). OGTT, scheduled for all women, was 
performed at mean±SD 26.4±2.2 gestational weeks, when the duration of the 
intervention was a mean of 12.5±3.1 weeks. At any stage of pregnancy, 119 (30.0%) 
and 175 (43.8%) of the participants were diagnosed with GDM with Finnish and 
IADPSG criteria, respectively. At 24–28 gestational weeks, 94 (24.9%) women 
developed GDM according to the Finnish criteria and 145 (38.3%) with the IADPSG 
criteria.  
5.2 Intervention with fish oil and probiotics 
5.2.1 Incidence of GDM in the intervention groups 
No significant difference in the incidence of GDM at mean 26 gestational weeks was 
found between the intervention groups (p>0.76 with both criteria) (Figure 5). 
Furthermore, after excluding the early OGTT positive women from the analysis, no 
differences in the incidence of new GDM diagnosis or OGTT values were detected 
between the groups (p> 0.58 with both criteria). 
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Table 5. Characteristics of the women.  
  n* Mean ± SD or n (%) 
Age 110/109/109/110 30.6 ± 4.6 
Prepregnancy weight (kg) 110/109/109/110 82.8 ± 13.5 
Prepregnancy BMI (kg/m²) 110/109/109/110 29.7 ± 4.2 
overweight   266 (60.7) 
obese   172 (39.3) 
Primipara 110/109/109/110 210 (47.9) 
Ethnic region 110/109/109/110  
European  430 (98.2) 
Asian  2 (0.5) 
Middle Eastern  3 (0.7) 
other/mixed  3 (0.7) 
College or university education 100/94/99/98 239 (61.1) 
Previous gestational diabetes 110/109/109/110 40 (9.1) 
Family history of diabetes 93/89/94/86 61 (15.6) 
Smoking during pregnancy 100/95/98/98 19 (4.9) 
Gestational weeks at 1st visit 110/109/109/110 13.8 ± 2.1 
Gestational weeks at 2nd visit 93/95/92/92 35.2 ± 0.9 
Gestational weeks at last weight measurement 95/96/95/92 38.1 ± 2.1 
Modified from Pellonperä et al. 2019, studies I and II. *order of the groups: fish oil + placebo, 
probiotics + placebo, fish oil + probiotics, placebo + placebo 
 
 
Figure 5.  Incidence of GDM (%) according to the intervention groups. New diagnosis= the early 
OGTT positive women excluded from the analysis A) Finnish criteria B) IADPSG criteria. 
No significant differences between the intervention groups were detected (p>0.55 for all 
comparisons, χ2 test). 
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In early gestation, 132 women at high risk for GDM were referred to OGTT (after 
randomization) at a mean 14.7±2.0 gestational weeks and 36 (27.9%) were 
diagnosed with GDM according to the Finnish criteria, and 61 (47.3%) according to 
the IADPSG criteria. 
Every fifth (24/119, 20.2%) woman diagnosed with GDM (Finnish criteria) 
needed insulin or metformin for the management of GDM (p=0.33 between the 
intervention groups). The effect of the intervention on the incidence of new GDM 
diagnoses at 24–28 weeks of gestation was not influenced by confounding factors 
including compliance or duration of the intervention, maternal age <35 or ≥35 years, 
prepregnancy BMI, gestational weight gain between study visits, consumption of 
fish oil or probiotic supplements before randomization, family history of diabetes, 
or previous GDM (p>0.05 for confounding factor × group interactions in all 
comparisons). 
5.2.2 Glucose and insulin concentrations 
Fasting glucose concentrations decreased, and the insulin concentrations and 
HOMA2-IR rose significantly in all intervention groups from early to late gestation 
(Figure 6). However, no significant differences were discovered in the change of 
glucose or insulin concentrations or HOMA2-IR between the intervention groups 
(p>0.1).  
 
Figure 6.  Change in fasting glucose, insulin and HOMA2-IR concentrations between early and 
late pregnancy study visits according to the intervention groups (mean and sd). No 
significant differences between the intervention groups were found (p>0.11 for all 
comparisons, One-way ANOVA).  
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5.2.3 GWG and body composition in intervention groups 
GWG was not influenced by the fish oil and/or probiotic intervention (Table 6). The 
proportions of women either exceeding, falling below or adhering to the GWG 
recommendations were also essentially similar between the groups. Additionally, we 
found no differences among the intervention groups in body composition at the first 
or the second study visit, or in the change of body composition between the visits 
(Table 6). 
The change in physical activity or the dietary intake of energy did not differ 
among the intervention groups (p>0.3 in both comparisons). 
Table 6. Gestational weight gain (GWG) and body composition in the intervention groups. 
 n 
Fish oil  
+ 
Placebo 
Probiotics 
+ 
Placebo 
Fish oil  
+ 
Probiotics 
Placebo 
+ 
Placebo p 
GWG       
GWG between 1st and 2nd 
visit (kg) 94/95/92/92 9.3 ± 3.5 9.3 ± 3.8  9.2 ± 4.0  9.2 ± 4.3  1.00* 
GWG from randomization to 
the end of pregnancy (kg) 95/96/95/92 12.2 ± 4.3 11.7 ± 4.7 11.8 ± 5.4  11.7 ± 5.4 0.93* 
Ideal weekly GWG rate from 
randomization n (%) 95/96/95/92 3 (3.2) 14 (14.6) 9 (9.5) 11 (12.0) 
0.17† Excess weekly GWG rate from randomization n (%) 95/96/95/92 87 (91.6) 78 (81.3) 79 (83.2) 74 (80.4) 
Inadequate weekly GWG rate 
from randomization n (%) 95/96/95/92 5 (5.3) 4 (4.2) 7 (7.4) 7 (7.6) 
Body composition       
∆ Body fat percentage (% 
points) 93/95/91/90 -2.4 ± 2.2 -2.6 ± 2.7  -2.2 ± 2.5 -2.5 ± 2.9  0.80* 
∆ Fat mass (kg) 93/95/91/90 1.7 ± 3.1 1.5 ± 3.5 1.8 ± 3.4  1.7 ± 4.0  0.96* 
∆ Fat  free mass (kg) 93/95/91/90 7.5 ± 2.0  7.8 ± 2.4 7.4 ± 2.2  7.6 ± 2.2 0.67* 
*one-way ANOVA, † χ² test. Women were divided into different GWG classes according to the 
recommendations issued by Institute of Medicine (2009). Modified from Pellonperä et al., study II. 
5.2.4 Maternal and neonatal outcomes 
There were no differences in maternal pregnancy outcomes among the intervention 
groups, including numbers of miscarriages, hypertensive complications, preterm or 
post term deliveries, or mode of delivery (p>0.23 in all comparisons). In addition, 
there was no difference in the postpartum hemorrhage (ml) or in the number of 
women bleeding over 1000ml among the intervention groups (p>0.82 in both 
comparisons). Furthermore, the neonatal outcomes did not differ among the 
intervention groups (including numbers of 5 min Apgar scores and birth weight, 
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macrosomia, congenital malformations, hypoglycemia, or admittance to neonatal 
intensive care unit, p>0.05 in all comparisons).  
5.3 Body composition 
5.3.1 GWG and body composition 
The mean GWG between prepregnancy and the last measurement (1.6±1.6 weeks 
before delivery) was 13.0 ± 6.3 kg (n=378). With respect to the weight gain between 
the study visits, 18% was FM and 82% FFM. On average, FM and FFM increased 
1.7 ± 3.5 kg and 7.6 ± 2.2 kg between the study visits respectively, thus BF% 
decreased by 2.4 ± 2.6 percentage points. Overweight women gained significantly 
more weight and FM than obese women (p<0.001 in both comparisons), while there 
was no difference in terms of FFM gain (p=0.34) (Figure 7). Consequently, the 
proportion of body fat decreased in both overweight and obese women, but 
significantly more in obese women (-1.8 ± 2.6 vs. -3.4 ± 2.3 percentage points, 
p<0.001).  
 
Figure 7. Weight and body composition changes in overweight and obese women (mean and sd). 
GWG= gestational weight gain, ∆BF%= change in body fat percentage, ∆FM=change in 
fat mass, ∆FFM=change in fat free mass. *p< 0.001 (One-way ANOVA). 
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5.3.2 Thoracic gas volume (TGV) 
The measurement of TGV was successful in 100/110 women in early gestation and 
106/110 women in late gestation. From early to late pregnancy, measured TGV 
reduced significantly (p=0.0002). The use of predicted instead of measured TGV led 
to a significant overestimation of 0.37 kg and 0.75 kg of FM in early and late 
pregnancy, respectively (Figure 8). As predicted TGV was higher in both early and 
late pregnancy (6.3% and 12.6% respectively), FM and BF% values calculated with 
the predicted TGV were 0.8% and 1.1% higher in early pregnancy, and 2.6% and 
2.0% higher in late pregnancy, respectively (p≤0.002 for all comparisons). In studies 
I and II, measured TGV was used in the calculations of body composition whenever 
possible (385/438 in early gestation and n=341/369 in late gestation). 
 
Figure 8. Mean fat mass (FM) and body fat percentage (BF%) calculated with measured and 
predicted thoracic gas volume (significant difference in all comparisons, p≤0.002, paired 
samples t-test). Data were available for 100 and 106 participants at the first and second 
study visits, respectively.  
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5.3.3 Weight gain according to the recommendations of the 
Institute of Medicine 
Most women, 77% (85/110), exceeded the recommended weight gain rate whereas 
11% gained weight inadequately. Only women with excess GWG gained FM on 
average (Figure 9). Although subjects with excessive GWG rate also gained more 
FFM, BF% diminished significantly less than in subjects with appropriate GWG.  
Women with inadequate GWG lost significantly more FM than women with 
appropriate weight gain, whereas no difference in the change of FFM was detected.  
No significant difference was detected in the energy intake, dietary quality or 
physical activity among the groups of appropriate, inadequate and excess GWG 
(p≥0.092 in all comparisons). 
 
Figure 9. Adherence to the IOM GWG recommendations between the study visits vs. change in 
body composition (means and standard deviations). GWG= gestational weight gain, 
∆BF%= change in body fat percentage, ∆FM=change in fat mass, ∆FFM=change in fat 
free mass. Inadequate GWG n=12 (10.9%), appropriate GWG n= 13 (11.8%), excess 
GWG n=85 (77.3%). * p<0.05. Inadequate and excess weight gains are compared with 
appropriate weight gain (one-way ANOVA with Games-Howell post-hoc tests). 
2,8
-3,44
6,2
-5,5
5
-1,21
6,2
-3,7
10,6
2,7
7,9
-1,9
-10
-5
0
5
10
15
Δweight (kg) ΔFM (kg) ΔFFM (kg) ΔBF%
ga
in
s 
in
 k
g 
or
 %
-p
oi
nt
s
Inadequate Appropriate Excess
**
*
*
Results 
 59 
5.3.4 Lifestyle 
5.3.4.1 Diet 
The daily consumption of energy did not change significantly between the early and 
late gestation (p=0.4). Nonetheless, the daily consumption of fat enhanced and 
consumption of carbohydrates as a proportion of energy intake (E%) reduced 
significantly over the follow-up (Figure 10). 
No significant change was discovered in the dietary quality (IDQ points) 
between early and late gestation (9.8±2.2 vs. 9.8±2.1, p=0.81). The quality of diet 
was assessed as poor in 50 % of the women in early gestation and 42% of the women 
in late gestation. 
The poor quality of diet was reflected in maternal body composition, as the 
amount of FFM was reduced in subjects with a poor quality of diet as compared to 
those subjects with good dietary quality (in early gestation 45.8±4.7 kg vs. 
48.8±5.8 kg, p=0.004 and in late gestation 53.4±5.6 kg vs. 56.1±6.4 kg, p=0.025). 
 
Figure 10. Change in the intakes of energy yielding nutrients from early to late pregnancy. *p= 
0.001(fat), p= 0.005 (carbohydrates), Paired samples t-test. Data obtained from 3-day 
food diaries filled in by 99 women in both early and late gestation. 
Regarding the energy yielding nutrients, protein intake (g) was found to correlate 
positively with FFM in early and late pregnancy (r=0.31, p=0.002 and r=0.39, 
p<0.001 respectively). No other correlations were discovered between body 
composition measures and intakes of other macronutrients, total energy intake or 
dietary quality.  
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5.3.4.2 Physical activity 
Between the two study visits, physical activity of the women was reduced from the 
median of 5.0 h/week (IQR 2.0–12.0) to 3.0 h/week (IQR 0.2–11.0), p<0.001. 
Body composition variables did not correlate with physical activity or the change 
in physical activity in either early or late gestation (data not shown). Furthermore, 
no significant associations were discovered in a linear model assessing the relation 
of physical activity with a change in body composition (data presented in Pellonperä 
et al. 2019, study III, Supplementary Table 2). 
5.3.5 GDM 
Compared to the women without GDM, the women diagnosed with GDM at any 
stage of pregnancy were significantly older, less educated, had higher prepregnancy 
weight and BMI, had more often a history of GDM and parents with diabetes 
(p<0.034 for all comparisons). The women with GDM also had their last weight 
measurement before delivery earlier in gestation than non-diabetic women. These 
factors were accounted for in the adjustments of the results, when the weight and 
body composition of healthy women and women with GDM were compared. As 
knowledge of GDM diagnosis potentially affects the lifestyle behavior of the 
women, only Finnish criteria were applied, when weight and body composition were 
analyzed. 
Women with GDM gained less weight than women without GDM between the 
study visits (p<0.001, Figure 11). The proportion of women with excessive weekly 
weight gain rate was greater and the proportion of inadequate weekly weight gain 
rate lower in women without GDM than in women with GDM (adjusted p=0.004).  
In early pregnancy, women diagnosed with GDM at any stage of pregnancy had 
more FM and greater BF% than women without GDM (p<0.02 in both comparisons). 
However, after adjusting for confounding factors, especially with prepregnancy 
BMI, the differences were no longer statistically significant. At the second visit in 
late gestation, women with an established GDM had less FM and lower BF% than 
women without GDM (adjusted p=0.003 and p= 0.026 respectively). The change in 
body composition from early to late pregnancy was also significantly different 
between women with GDM and non-diabetic women: less FM was gained and BF% 
was reduced more in women with GDM (p<0.001 and p=0.011, respectively), while 
no difference between the groups was found in the change of FFM (Figure 11). 
When the early gestation OGTT positive women were removed from the 
analyses (n=27), the adjusted results remained essentially same, i.e. the body 
composition at the first visit did not differ between non-diabetic women and women 
who later developed GDM.  
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Correlations between lifestyle variables (change in energy intake, carbohydrates, 
fat, protein and physical activity assessed by MET-index) and change in body 
composition were not detected in all women, or in women with or without GDM 
(r<0.21). 
 
Figure 11. GWG and the change in body composition in women with and without GDM (adjusted 
means and standard errors). GWG and body composition variables were assessed as 
gains between the two study visits. GWG= gestational weight gain, ∆BF%= change in 
body fat percentage, ∆FM=change in fat mass, ∆FFM=change in fat free mass. 
*Significant difference analyzed with linear model adjusted for age, prepregnancy BMI, 
previous GDM and intervention group.  
5.3.6 Fetal weight and amniotic fluid 
The average estimated fetal weight was 2623 g (± 327 g) and mean amniotic fluid 
index (AFI) was 12.7 cm (±3.75 cm) at mean 35 gestational weeks (n=103). 
Estimated fetal weight correlated with maternal FFM in early and late pregnancy 
(r=0.31, p=0.003 and r=0.36, p<0.001 respectively), and with the change of maternal 
FFM (r=0.34, p<0.001). In contrast, there was no correlation between AFI and body 
composition measures (r<0.16, p>0.1). 
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6 Discussion 
Obesity and GDM are worldwide problems that challenge the care of pregnant 
women. The perception that maternal physiology, body composition, and lifestyle 
exerts a profound and lasting influence on their offspring’s long-term health through 
metabolic programming, has been supported by solid data from epidemiological, 
medical and basic science studies (Barker and Thornburg 2013, Fleming et al. 2018). 
This theory of ´Developmental Origins of Health and Disease’, presents a vicious 
cycle as offspring of the obese mothers with GDM are more prone to obesity, 
hypertension and disturbances in glucose metabolism. Thus, it would be most 
desirable to break this cycle, as well as reduce maternal short- and long-term 
complications. However, the prevention of GDM has proven to be very difficult. 
Interventions to prevent or take care of these conditions are an area of intensive 
research, and several new studies emerged also during the conductance of our trial. 
Different interventions have been tried, but with limited or no success. 
Unfortunately, the trial presented in this thesis with fish oil and probiotics falls 
within this category of ineffectual interventions. As also proposed by others (Egan 
and Simmons 2018, Fleming et al. 2018), GDM and the resulting programming of 
offspring health may only be prevented if interventions are initiated before 
conception or at the latest, in the first trimester. However, novel information of the 
effects of lifestyle, GWG and GDM on maternal body composition was provided in 
the studies presented here. 
6.1 Intervention with fish oil and probiotics 
Previous studies with n-3 LC-PUFA and probiotics indicate that these food 
supplements may help in the management of glucose levels in women with GDM 
(Gao et al. 2018, Karamali et al. 2016, Kijmanawat et al. 2018), and in the case of 
probiotics, also prevent GDM (Laitinen et al. 2009, Luoto et al. 2010, Wickens et al. 
2017). In the present trial, no benefit was detected on glucose metabolism or on the 
incidence of GDM with these food supplements as compared to placebo. Only one 
large study has been published on the effect of n-3 LC-PUFA on the prevention of 
GDM as a main outcome, this appearing after the planning of present trial with fish 
oil and probiotics had been started. The results were similar as presented here, 
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although the dose of DHA and EPA were considerably smaller (Zhou et al. 2012). 
With regard to probiotics, the positive findings mentioned above have been 
challenged by two trials (Callaway et al. 2019, Lindsay, K. L. et al. 2014). 
Resembling the results presented here, these studies showed that a) L. Salivarius and 
b) L. Rhamnosus and Bifidobacterium lactis consumed by overweight/obese women 
do not improve glucose metabolism or prevent GDM.  
With respect to loss of weight and FM, several recent systematic reviews and 
meta-analyses focusing on overweight or obese non-pregnant adults have found that 
probiotics are beneficial (Borgeraas et al. 2018, Crovesy et al. 2017). Similarly, the 
consumption of fish oil has been suggested to reduce weight and BF% in non-
pregnant individuals and in animals (Albracht-Schulte et al. 2018, Bender et al. 
2014). In pregnant women, studies measuring body composition in a probiotic or 
fish oil intervention are almost non-existent. Therefore, new information was 
generated in this trial. Unfortunately, no improvements in maternal weight or body 
composition with these food supplements were detected compared to placebo. 
This is the first time that the potential synergistic benefits of combining n-3 LC 
PUFA with probiotics have been investigated in pregnant women. The published 
literature on this topic is scanty; one previous study demonstrated promising 
synergistic results on insulin sensitivity in a population of healthy overweight adults 
(Rajkumar et al. 2014). Furthermore, there is previous experimental evidence 
indicating that a combination of these two active components might exert synergistic 
immunoregulatory effects (Kastel et al. 2007).  
The reason why no intervention effect was detected, separately or in 
combination, remains unknown, although several explanations can be speculated. It 
may be that the metabolic burden of obesity in our recruited women was so severe 
that it could not be overcome by the potential interventional effect in regulating 
glucose metabolism. Indeed, a previous study demonstrated more pronounced 
changes in both microbiota and markers of low-grade inflammation with increasing 
BMI (Houttu et al. 2018). Future analyses of inflammatory markers (hs-CRP and α1-
acid glycoprotein) of this study population will reveal if the intervention had any 
effect on low-grade inflammation. With regard to n-3 LC-PUFA, genetic variation 
may influence responsiveness to EPA and DHA, although the available evidence is 
relatively limited (Madden et al. 2011). Furthermore, the baseline concentrations of 
DHA and EPA in this study population are yet to be determined. If the concentrations 
were sufficiently high at the beginning, it could explain why n-3 LC-PUFA 
supplementation had very little influence on the measured outcomes. It has also been 
suggested that the ratio of EPA and DHA could influence the effects of an n-3 LC-
PUFA intervention, as a meta-analysis in patients with type 2 diabetes revealed that 
a high ratio of EPA to DHA could be beneficial in terms of glucose control (Chen, 
C. et al. 2015). This may be one reason why the fish oil intervention failed to exert 
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any glucose regulating benefit, as DHA was the dominant fatty acid in the fish oil 
consumed by the women. Other causes for the absence of an intervention effect could 
be related to the dose, timing and duration of intervention, compliance and the 
probiotic strains used.  
6.2 Factors affecting maternal body composition 
6.2.1 TGV 
According to previous studies conducted with ADP in non-pregnant individuals, 
TGV can be predicted, instead of measured, without significantly altering the body 
composition results (Collins and McCarthy 2003, Otterstetter et al. 2015), although 
a weight change may influence the measured TGV (Minderico et al. 2008).  
In the present study, compared to measured TGV, the usage of predicted TGV 
in body composition calculations led to an overestimation of FM and BF% that 
increased from around 1% to 2% during pregnancy. These results are in line with a 
former study pointing out that the prediction of TGV results in a relatively small but 
significant overestimation of BF% by 0.5% at 32 gestational weeks in subjects with 
normal BMI (Henriksson et al. 2013). The greater overestimation in the present study 
could be caused by the obesity of the women participating in this study, and also the 
more advanced gestational age at the time when the late pregnancy body composition 
measurements were made. These results also indicate that the overestimation 
increases during the pregnancy, which can be due to the growth of the uterus that 
might influence TGV by elevating the diaphragm. The finding of Most et al. (2018) 
suggesting that measurement of TGV by BodPod is difficult in pregnant women, was 
not supported by this study, as successful measurement was attained in 96% of 
women in late pregnancy. 
Numerous factors, such as fasting state, clothing and emptiness of the bladder 
must be considered when body composition is measured with ADP. Pregnancy poses 
further challenges to the measurement of body composition, as specific gestational 
age and the increased hydration of FFM related to it have to be taken into account.  
As every attempt should be made to standardize and control all the factors possibly 
causing inaccuracies in the measurements, also the measurement of TGV can be 
recommended. 
6.2.2 Dietary intake and quality 
When the lifestyle determinants of body composition in this study are considered, 
good quality of diet and daily consumption of protein were found to positively 
correlate with FFM in early and in late gestation. The role of FFM during pregnancy 
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is not well defined, although it is suggested that maternal FFM correlates with 
offspring birth weight and FFM (Henriksson et al. 2015, Kent et al. 2013). Indeed, 
as 85-90% of fetal weight is FFM (Catalano, P. M. et al. 2003, Koo et al. 2000), fetal 
tissues comprise a significant proportion of maternal FFM gain, which averaged 7.6 
kilograms in late pregnancy in this study. 
FFM consists mainly of water and protein, and is the main determinant of the 
basal metabolic rate, which in turn, is an essential component of total energy 
expenditure (Hronek et al. 2011, Lof et al. 2005, Pipe et al. 1979). Protein intake has 
been suggested to decrease GWG as a result of higher energy expenditure because 
the thermogenesis of protein is larger than that of carbohydrate or fat (Raben et al. 
2003).  In the current study, the consumption of fat was elevated above the 
recommended gestational dietary reference intakes issued by the IOM (Institute of 
Medicine 2002/2005). Meanwhile, the consumption of carbohydrates decreased, and 
although the consumption of protein stayed constant, it was not at a particularly high 
level. The protein requirement is increased during pregnancy in order to deliver 
sufficient amino acids for protein synthesis in maternal, fetal, and placental tissues. 
In a study with rodents, a maternal diet with a low protein intake has been shown to 
be related to changes in the pancreatic islets of Langerhans of the offspring, possibly 
resulting in glucose intolerance in later life (King et al. 2019). Furthermore, the 
replacement of carbohydrates with fat may increase lipolysis, free fatty acid 
concentrations, and maternal insulin resistance (Hernandez et al. 2018). All things 
considered, instead of increasing fat intake, sufficient protein consumption and 
intake of high-quality nutrient-dense carbohydrates could exert health benefits for 
both mother and child.  
6.2.3 GWG 
Compared to the previous literature also involving overweight and obese women 
(Berggren et al. 2016, Deputy et al. 2015), in the present study, even a greater 
proportion of subjects exceeded the GWG recommendations. The excess GWG led 
to increased body adiposity, which is in line with previous research (Berggren et al. 
2016, Widen et al. 2015). Furthermore, the results of the present study are also in 
agreement with the concept that both the GWG and the increase in FM are inversely 
proportional to the pre-pregnancy BMI, as overweight women gained significantly 
more weight and FM than obese women. Interestingly, the recommended ideal GWG 
was reached by the gain of FFM alone, as also reported by Most et al. (2019). In 
women with ideal and inadequate GWG, the energy demands for fetal growth were 
likely to be met by the mobilization of maternal FM. 
While the negative impact of excess GWG on pregnancy complications and 
offspring health is clear, the harmfulness of inadequate weight gain among the 
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overweight and obese women is still under debate (Catalano, P. 2018, Oken et al. 
2009). However, there is an indication that in obese women, the weight loss or gain 
<5 kg is associated with an increased risk of small for gestational age infants and 
decreased neonatal FM, FFM, head circumference, and, also with a higher risk of 
hypertension and insulin resistance in future life (Catalano, P. M. et al. 2014, Tam, 
C. H. T. et al. 2018). In present study, 11% of women gained weight inadequately 
and lost significantly more FM (3.4 vs 1.2 kg) as compared with women with an 
appropriate weight gain, which could affect the future growth and cardiometabolic 
health of their children. 
6.2.4 GDM 
The body composition of women with GDM has not been widely examined. A few 
studies have evaluated the possibility of early pregnancy body composition as a way 
of predicting the development of GDM. These studies have indicated that 
ultrasonographically measured visceral fat thickness is associated with GDM or 
higher glucose values (Bartha et al. 2007, De Souza et al. 2016, Martin, A. M. et al. 
2009). Likewise, a few studies conducted with bioimpedance analysis have reported 
that truncal fat gains between 15–28 gestational weeks or FM and BF% measured at 
21–24 gestational weeks are related to the onset of GDM (Sommer et al. 2014, Xu 
et al. 2016). Our results indicate that after adjustment for BMI and other confounding 
factors, body composition measured with ADP in early pregnancy is not different 
between women who later develop GDM and women without GDM.  
Regarding late pregnancy, the data presented here on body composition of 
women with GDM is novel. Our results indicate that in late pregnancy, the adiposity 
of diabetic women falls below that of women without GDM. The reason for this 
finding remains unclear. The most logical explanation would be that the treatment 
of GDM would result in positive lifestyle changes and improvements in body 
composition. However, we could not find any correlation between lifestyle changes 
and body composition changes in those women who developed GDM as compared 
to those not displaying this condition. Previously, a small study has been conducted 
to investigate the relationship of GDM and changes of body composition over 
pregnancy (Ehrenberg et al. 2003). These researchers used hydrodensitometry to 
measure body composition before conception, at 12–14 gestational weeks and at 33–
36 gestational weeks. Although the trial included only 19 patients with GDM and 33 
controls, the gains of FM tended to be smaller and BF% reduced in diabetic women 
(p=0.08 and p= 0.07 respectively), which is in line with our results. While it is 
unclear what causes the greater weight gain in healthy women as compared to 
diabetic women, it does seem clear that the excess weight gained is mainly FM and 
not FFM. 
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6.2.5 Fetal weight and amniotic fluid 
In this study, fetal weight estimation correlated positively with maternal FFM 
explaining around 13% of the variation in FFM.  This indicates that fetal tissues, 
which are mainly FFM (Catalano, P. M. et al. 2003, Koo et al. 2000), should be 
considered when interpreting the FFM results. Instead, the amount of amniotic fluid 
was not related with maternal FFM. This could be attributable to an inaccuracy in 
the AFI-method reflecting the true amniotic fluid volume (Phelan et al. 1987), a 
variation in hydration of maternal tissues and small variation in AFI values, as 99% 
of subjects had an AFI within the normal range. 
6.3 Strengths and limitations 
This was a well conducted prospective trial with a large sample size and a small 
drop-out rate. Regarding the nutritional intervention, this was also a double-blind, 
placebo-controlled trial. Nonetheless, some limitations are acknowledged. The study 
was only powered for primary outcomes of the food supplement intervention 
(incidence of GDM and fasting glucose in late pregnancy), and not for secondary 
outcomes such as body composition or GWG. However, when inspecting the results 
of body composition among the intervention groups with high p-values, and the great 
variance in body composition, it is unlikely that even a considerably larger sample 
size would have yielded statistically significant or clinically meaningful differences. 
Regarding the relation of GDM to body composition, further research is needed to 
confirm the findings of this study. 
Limitations relate also to the method of measuring body composition. ADP does 
not allow for the estimation of alterations in intra-abdominal or visceral fat, which 
could have provided meaningful information especially regarding the comparisons 
of diabetic and non-diabetic women. Furthermore, fetal tissues cannot be 
distinguished from maternal tissues. This might influence the findings, as fetal 
growth is heterogeneous especially in late gestation and, additionally, there are 
variations in the amount of amniotic fluid and the size of the placenta. The same 
challenges apply in general for the analysis of body composition during pregnancy, 
but nevertheless ADP has been proposed to be the preferred method for the 
determination of maternal FM in late gestation and provides more accurate 
information on body adiposity than BMI (Marshall et al. 2016).  
In addition, the compliance with the intervention could have been more precisely 
determined; especially the biomarkers related to the consumption of fish oil 
supplements could have been measured. The concentrations of plasma phospholipid 
fatty acids of the women participating in this trial are still to be analyzed.  
With regard to the evaluation of the lifestyle, diet and physical activity were 
evaluated only twice during the pregnancy which could be a study limitation; more 
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frequent exploration could improve the accuracy in evaluating the associations with 
the body composition, although, the compliance in recordings could also be 
hampered. Moreover, the reliability of methods assessing energy intake (self-
reported food diaries) has been questioned, suggesting that there could be 
inconsistencies between reported and actual energy intake (Dhurandhar et al. 2015). 
However, the reliability should be increased by the fact that repeated measurements 
were conducted on the same women and we had a relatively large sample size. 
Another limitation may be attributable to the recruitment procedure in which the 
women contacted the study personnel, and consequently it is likely that these women 
were more motivated to pay attention to their lifestyle than the average overweight 
and obese women. Nonetheless, the majority of our subjects gained weight in excess 
of the IOM guidelines, and even more often than indicated in the previous literature, 
which may partly contradict this argument. Additionally, a control group of normal 
weight women could also have provided important information in comparisons 
related to the intervention, as previous positive effects on glucose metabolism were 
detected in women with a predominantly normal BMI. However, considerably more 
women would have been required to be recruited to maintain the statistical power. 
Interventions to reduce the risk of GDM are proposed to be more efficient, if 
initiated in the first trimester or even before (Egan and Simmons 2018). The 
recruitment of overweight and obese women only planning a pregnancy was also 
considered when this trial was designed, but the execution of this design was thought 
to be both difficult and impractical. However, many steps were taken to recruit 
women as early as possible, which resulted in a mean duration of intervention of 
over 12 weeks, which must be considered as reasonably good as compared to most 
of the trials conducted with these food supplements. 
As the effects of probiotics can be strain specific and the effects of n-3 LC-PUFA 
dose dependent, the use of other strains and different doses could have yielded 
different results. However, there was indication from the previous study that these 
probiotics, namely Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12, 
could exert favorable effects on glucose concentrations (Laitinen et al. 2009).  
Since there was little knowledge regarding the role of fish oil and probiotics in 
pregnant women, and the body composition determinants of overweight and obese 
women with, or without GDM, new information was generated in the studies 
included in this thesis. 
6.4 Clinical implications 
According to the results of this study, the utilization of the strains of probiotics and 
the dose and ratio of n-3 LC-PUFA used in this trial cannot be recommended to be 
consumed to improve glycemic status or to reduce adiposity in overweight and obese 
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pregnant women. If the previous literature (Callaway et al. 2019, Zhou et al. 2012) 
about this issue is considered alongside the results of this study, the evidence clearly 
implies that these interventions do not appear to yield benefits in terms of glucose 
metabolism, at least in overweight and obese pregnant women. Fortunately, no safety 
concerns were raised in this study, which is important when the possible use of these 
food supplements are considered for other indications, particularly to improve child 
health.  
In this study, fat intake increased above recommendations alongside with excess 
GWG and FM accrual, while the carbohydrate intake decreased. Therefore, it is 
proposed that overweight and obese women are counselled to avoid augmentation of 
fat, especially saturated fat, while sufficient intakes of high-quality nutrient-dense 
carbohydrates and protein should be ensured. These adjustments to the diet are 
already possible within current nutritional recommendations (Institute of Medicine 
2002/2005, Nordic Council of Ministers 2014), and thus may be implemented by 
counseling the pregnant women. However, to achieve appropriate GWG, obese 
women should gain no FM, and the energy intake of obese women should not 
increase during pregnancy (Most et al. 2019).  
6.5 Future aspects 
The intervention trial with fish oil and probiotics was designed to investigate the 
effects of the intervention on maternal and child health. Probiotics have been 
proposed to reduce maternal postpartum depression and eczema of the child, and fish 
oil supplementation may reduce preterm birth and sensitization to certain foods in 
the child (Garcia-Larsen et al. 2018, Middleton et al. 2018, Slykerman et al. 2017). 
The possible effects of this on-going trial on outcomes other than GDM and maternal 
body composition, remain to be examined in further analyses of the data. 
Particularly, the potential benefits on child health over both the short and the long 
term need to be evaluated. 
The literature concerning the body composition of women diagnosed with GDM 
is almost non-existent. Future studies will be required to confirm our discovery of 
reduced adiposity of women with GDM as compared to women without GDM and 
to investigate the role of treatment and other probable causes behind this finding. 
Another area of interest that needs further clarification is to identify the factors that 
contributed to either the appropriate or the inadequate GWG in the overweight and 
obese women participating in this trial. 
The harmful role of excess maternal fat on pregnancy outcomes has been clearly 
demonstrated. The results of this study raised a question of the role of maternal FFM 
on pregnancy outcomes. Further studies are necessary to assess the impact of 
maternal FFM on outcomes other than birth weight. 
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It seems clear that there are no easy ways to reduce maternal adiposity and the 
pregnancy complications related to it, when women are already pregnant. Therefore, 
interventions to normalize body composition should be introduced earlier, probably 
already during childhood and as a part of health education in school. Enlightened 
health-policy decisions will be required to promote this goal, in conjunction with 
inexpensive healthy eating and sufficient physical activity. 
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7 Conclusions 
1. Although safe, the administration of n-3 LC PUFA (1.9g DHA and 0.22g EPA) 
and/or Lactobacillus rhamnosus HN001 and Bifidobacterium animalis ssp. 
lactis 420 does not reduce the risk of GDM, improve fasting glucose 
concentrations or reduce insulin resistance as compared to placebo in overweight 
and obese women (Study I). Additionally, this intervention does not affect GWG 
or maternal body composition as compared to placebo (Study II).   
2. Women with GDM gain less FM than normoglycemic women. The body 
composition of overweight and obese women in early pregnancy does not predict 
the development of GDM at approximately 24–28 gestational weeks. (Study II).  
3. Dietary protein intake and better diet quality were positively correlated with 
maternal FFM, while energy intake and physical activity were not associated 
with body composition. Compared to women with appropriate GWG, women 
with excess GWG gained more FM while women with an inadequate GWG lost 
more FM. Even appropriate GWG results in a mean reduction of FM in obese 
women. (Study III).  
4. Measured TGV differs significantly from predicted TGV in pregnant women in 
early and late gestation. Measurement of TGV provides more accurate estimates 
of maternal adiposity than can be attained by prediction of TGV. (Study IV). 
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